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resumo 
 
 
As células da microglia são células imunes residentes no sistema nervoso 
central (SNC) e desempenham um papel importante em processos 
neuroinflamatórios. Estas células são responsáveis por monitorizar o 
parênquima neuronal, sendo capazes de responder rapidamente a danos no 
SNC. Após ativação, a microglia altera a sua morfologia e o seu perfil de 
expressão de proteínas. O processo de ativação induz a proliferação, migração 
para a foco da lesão, aumento da capacidade fagocítica, bem como produção 
e libertação de espécies reativas de oxigénio (EROs), espécies reativas de 
azoto e citocinas (pro- e anti-inflamatórias). A ativação da microglia é essencial 
para a reparação de tecidos e a manutenção da homeostasia do SNC. No 
entanto, a ativação crónica ou a sua desregulação podem contribuir para a 
patofisiologia de doenças neurodegenerativas. Assim sendo, o estudo dos 
mecanismos subjacentes à ativação das células da microglia é importante para 
ajudar a definir e desenvolver estratégias terapêuticas apropriadas para 
prevenir a sua ativação crónica. Um estudo anterior reportou o aumento dos 
níveis de RNAm da profilina (Pfn) em células da microglia no hipocampus de 
ratos após lesão unilateral no córtex entorrinal, sugerindo que a Pfn poderá 
estar envolvida no processo de ativação da microglia. A Pfn1 é uma proteína 
de ligação à actina que regula a polimerização do citoesqueleto de actina, 
sendo importante em diversos processos celulares, incluindo motilidade, 
proliferação e sobrevivência. Neste trabalho, nós estudamos o papel da Pfn1 
na função da microglia. Para tal, utilizamos linhas celulares e células primárias 
de microglias corticais de rato nas quais reduzimos a expressão da Pfn1 e 
avaliamos o seu estado de ativação com base em marcadores clássicos de 
ativação, tais como: fagocitose, libertação de glutamato, produção e libertação 
de EROs e citocinas pro- e anti-inflamatórias. Nós demonstramos que a Pfn1 
(i) se encontra mais ativa após estímulo da microglia por hipoxia, (ii) modula as 
assinaturas pro- e anti-inflamatória da microglia e (iii) desempenha um papel 
importante na produção de EROs pela microglia. Nesse estudo concluímos 
que a Pfn1 é uma proteína importante para o funcionamento da microglia, 
desempenhando um papel essencial na ativação da microglia, 
independentemente da polarização pró ou anti-inflamatória. 
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abstract 
 
Microglial cells are the resident immune cells of central nervous system (CNS) 
and the major players in neuroinflammation. These cells are also responsible 
for surveilling the neuronal microenvironment, and upon injury to the CNS they 
change their morphology and molecular profile and become activated. 
Activated status is associated with microglia proliferation, migration to injury 
foci, increased phagocytic capacity, production and release of reactive oxygen 
species (ROS), cytokines (pro- or anti-inflammatory) and reactive nitrogen 
species. Microglia activation is crucial for tissue repair in the healthy brain. 
However, their chronic activation or deregulation might contribute for the 
pathophysiology of neurodegenerative diseases. A better understanding of the 
mechanisms underlying microglial cell activation is important for defining 
targets and develop appropriate therapeutic strategies to control the chronic 
activation of microglia. It has been observed an increase in profilin (Pfn) mRNA 
in microglial cells in the rat hippocampus after unilateral ablation of its major 
extrinsic input, the entorhinal cortex. This observation suggested that Pfn might 
be involved in microglia activation. Pfn1 is an actin binding protein that controls 
assembly and disassembly of actin filaments and is important for several 
cellular processes, including, motility, cell proliferation and survival. Here, we 
studied the role of Pfn1 in microglial cell function. For that, we used primary 
cortical microglial cell cultures and microglial cell lines in which we knocked 
down Pfn1 expression and assessed the activation status of microglia, based 
on classical activation markers, such as: phagocytosis, glutamate release, 
reactive oxygen species (ROS), pro- and anti-inflammatory cytokines. We 
demonstrated that Pfn1 (i) is more active in hypoxia-challenged microglia, (ii) 
modulates microglia pro- and anti-inflammatory signatures and (iii) plays a 
critical role in ROS generation in microglia. Altogether, we conclude that Pfn1 is 
a key protein for microglia homeostasis, playing an essential role in their 
activation, regardless the polarization into a pro or anti-inflammatory signature. 
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1. Introduction 
1.1. Microglia  
Microglial cells, the resident immune cells of central nervous system (CNS), are 
responsible for the surveillance of the neural microenvironment quickly responding to altered 
neuronal activity and injury. The concept of microglia as a defined cellular element of the CNS was 
introduced by Ramón y Cajal and Pío del Río Hortega during 1920s (Kettenmann, Hanisch et al. 
2011). Microglial cells constitute up to 10% of the glial cells of the adult CNS, being 
heterogeneously distributed throughout different brain regions. The most microglia-enriched 
areas in the CNS are the hippocampus, olfactory bulb, telencephalon, basal ganglia and substantia 
nigra (Lawson, Perry et al. 1990). 
1.1.1. Origin and development  
Mice microglial cells derive from primitive myeloid progenitors that leave the yolk sac 
around E8.5–E9.0 and migrate to the neural tube via primitive bloodstream. The first precursors 
have low expression of cluster of differentiation 45 (CD45) and high expression of c-kit. After 
leaving the yolk sac, the progenitors begin to express lineage-specific genes and become 
differentiated into mature microglia. This population of microglia is maintained throughout life by 
self-renewal with little contribution from cells outside the CNS like bone-marrow macrophages 
(Salter and Beggs 2014). 
After arriving at the brain parenchyma, microglia alters its morphology and become 
ramified. This phenotype may be induced by adenosine triphosphate (ATP) (Hanisch 2002) and 
transforming growth factor beta (TGF-β) released by astrocytes (Schilling, Nitsch et al. 2001). 
Furthermore, microglial cell development is regulated by colony stimulating factor 1 (CSF-1) 
receptor and its ligand interleukin-34 (IL-34), which is mainly produced by neurons (Kettenmann, 
Hanisch et al. 2011, Salter and Beggs 2014).  
Although microglia and macrophage share immune functions and express diverse 
common proteins, such as CD11b, CD14 and EGF-like module-containing mucin-like hormone 
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receptor-like 1 (EMR1), they are highly distinguishable cell populations with different 
transcriptional patterns. There are growing evidences supporting the idea that microglial cells are 
not just classical immune effector cells, having critical functions in development, connectivity and 
plasticity of the CNS (Saijo and Glass 2011, Salter and Beggs 2014). 
1.1.2. Surveilling microglia 
In physiological conditions, microglial cells present a ramified morphology with thin and 
very motile processes that are continuously extending and retracting in order to sense the 
surrounding environment (fig. 1A). Microglial cells respond to neuronal activity and spread their 
processes toward active synapses, increasing the contact with highly active neurons. Microglial 
cells in homeostatic conditions are thus not in “resting” state, unlike what was previously thought. 
On the contrary, microglial cells are in a very active “surveilling” state (Salter and Beggs 2014). 
Such state is dependent on neuronal signals like CX3C-chemokine ligand 1 (CX3CL1), CD47, CD200 
and CD22 (fig. 1B) (Kettenmann, Hanisch et al. 2011, Saijo and Glass 2011). 
 
Figure 1 - Surveilling state of microglia. (A) Immunohistochemistry for ionized calcium-binding adapter molecule 1 
(Iba1) in mouse cortex shows microglia and its classical ramified morphology in surveilling state. Adapted from 
Kettenmann, Hanisch et al. 2011. (B) Surveilling state of microglia is maintained through signals released by neurons - 
CX3CL1 -, that are recognize by microglia receptor CX3CR1 and interaction between neuronal cell-surface proteins 
CD47, CD200 and CD22 and respective microglia receptors CD172, CD200R and CD45. Adapted from Saijo and Glass 
2011. CX3CL1: CX3C-chemokine ligand 1; CX3CR1: CX3C-chemokine receptor 1; CD: Cluster of differentiation. 
Several in vitro studies indicate that microglia can secrete proteins that are important for 
the growth and development of neurons, as well as important substances for maintaining 
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neuronal maturation. Examples of these neurotrophic factors are insulin-like growth factor 1 
(IGF1), brain-derived neurotrophic factor (BDNF) and TGF-β (Saijo and Glass 2011). Also, the 
phagocytic capacity of microglia is crucial for CNS development. During neurogenesis, a significant 
amount of neurons undergo programmed cell death and, in order to prevent damaging effects in 
the surrounding tissue, apoptotic neurons have to be quickly removed. Microglia can recognize, 
engulf and digest apoptotic neurons, contributing to the integrity of the nervous system (Peri and 
Nusslein-Volhard 2008). Moreover, these cells can sense neurons committed to die and can 
instruct neuronal apoptosis by secreting neurotoxic agents, for example tumor necrosis factor 
(TNF). Microglial cells are also critical for synaptic pruning, which consist in the elimination of 
excessive synapsis made by developing neurons (Saijo and Glass 2011, Salter and Beggs 2014). 
1.1.3. Activated microglia 
Microglia activation is a highly regulated process, in other to protect the brain 
parenchyma from damaging effects of an immune reaction. Microglia become activated upon 
diverse stimuli, ranging from altered neuronal activity, infections, trauma, ischemia to 
neurodegenerative diseases (Hausler, Prinz et al. 2002). During activation, microglia experience 
rapid and profound morphological changes, modifications in gene expression profile and 
functional behaviour. Activated microglia turn into an amoeboid-like phenotype with shorter and 
thicker processes and are able to proliferate and migrate to injury foci following chemotactic 
gradients released by neuronal or immune cells (Kettenmann, Hanisch et al. 2011). 
1.1.3.1. Activation process  
Microglial cells express a plethora of receptors that recognize multiple signs of 
homeostasis disturbance (fig.2), including receptors for pathogen-associated molecular patterns 
(PAMPs). These receptors, known as pattern-recognition receptors (PRRs), include toll-like 
receptors (TLRs) and NOD-like receptors (NLRs), among others. Besides pathogen recognition, 
TLRs also detect endogenous damage-associated molecular patterns (DAMPs), metabolic products 
or molecules released by dead cells (Saijo and Glass 2011).  
Classically, microglia activation is studied upon stimulus with bacterial endotoxin 
lipopolysaccharide (LPS), a component of the cell wall of Gram-negative bacteria. LPS is 
recognized by TLR4 and CD14, which triggers downstream signalling cascades dependent on 
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adaptor molecules such as myeloid differentiation primary response protein 88 (MYD88) and TIR 
domain-containing adaptor protein inducing IFNβ (TRIF). These signalling cascades lead to 
activation of JNK and p38 signalling pathways and activation of transcription factor nuclear kappa 
B (NF-κB) resulting in the transcription of pro-inflammatory regulators (Kawai and Akira 2010).  
Microglial cells also express diverse non-PRRs, important for recognition of DAMPs in CNS, 
such as purinergic receptors and receptors for advanced glycation end-products (RAGE). 
Purinergic receptors can detect nucleoside triphosphates released by damaged cells and activate 
downstream extracellular signal-regulated kinase (ERK) pathway, leading to signalling events that 
induce the transcription of pro-inflammatory mediators. On the other hand, RAGE receptors are 
able to detect glycation end-products and high-mobility group box 1 (HMGB1), a nuclear protein 
released by necrotic cells. HMGB1 detection also triggers the activation of pro-inflammatory 
genes (Saijo and Glass 2011). 
Microglia activation can be amplified by activated astrocytes (fig. 2), increasing the 
production of neurotoxic factors. Astrocytes express TLR4 and react to LPS, although with less 
extent than microglia. Activated astrocytes increase the expression of pro-inflammatory genes 
and CSF1 which promotes further microglia activation and microgliosis. In turn, microglia 
activation is responsible for increasing astrocyte activation by releasing factors like IL-1β and TNF, 
creating a feedback loop (Saijo and Glass 2011). 
1.1.3.2. Classical pro-inflammatory signature 
As mentioned above, microglial cells have different receptors and signalling pathways 
involved in the activation process. Different stimuli may induce distinct gene expression profiles 
leading to different phenotypes (fig.2). 
Microglia can be activated toward a classical pro-inflammatory phenotype in which cells 
release pro-inflammatory cytokines such as TNF, IL-1β and IL-6 and chemokines (Rojo, McBean et 
al. 2014). These molecules can further recruit other microglia in the vicinity and peripheral 
immune cells, affecting their activation state. Moreover, activated microglial cells phagocytose 
pathogens and present their antigens via major histocompatibility complex class II (MHCII) 
molecules. (Hanisch 2002, Saijo and Glass 2011).  
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Figure 2 – Microglia activation process. In healthy central nervous system (CNS), microglial cells are continuously 
scanning their microenvironment. Surveilling microglia have multiple receptors that recognize signs of homeostasis 
disturbance, such as: pattern-recognition receptors (PRRs), that includes toll-like receptor 4 (TLR4); purinergic receptors 
and receptors for advanced glycation end-products (RAGE). PRRs recognize pathogen-associated molecular patterns 
(PAMPs) present in bacteria and virus. For example, lipopolysaccharide (LPS), a component of the cell walls of Gram-
negative bacteria, is detected by TLR4. On the other hand, purinergic receptors and RAGE detect endogenous damage-
associated molecular patterns (DAMPs) released by damaged cells, for example: adenosine triphosphate (ATP), histones 
and High-mobility group box 1 (HMGB1). After exposure to these chemical signals, microglia become activated and 
respond rapidly and migrate toward injury foci. Morphologically, microglia became less complex and appears with an 
amoeboid shape. Activated microglia can acquire two distinct phenotypes: neurotoxic microglia (red) and phagocytic 
microglia (green). The first phenotype corresponds to a classical pro-inflammatory phenotype, in which microglia 
produce and release high amounts of pro-inflammatory cytokines; reactive oxygen species (ROS); reactive nitrogen 
species (RNS) and glutamate. This phenotype is important to protect CNS against pathogens or damaged cells. 
Although, the factors released by this activated microglia are also neurotoxic. On other hand, the second phenotype 
corresponds to an alternative activation state in which microglia have increased phagocytic ability, express wound 
healing genes, produce and release anti-inflammatory cytokines and molecules that promote tissue repair, such as 
trophic factors and pro-angiogenic factors. Microglia activation leads to astrocytes activation trough release of 
interleukin-1 beta (IL-1β) and tumor necrosis factor (TNF). In turn, activated astrocytes produce and release TNF and 
colony-stimulating factor 1 (CSF1), which amplify microglia activation thus generating a feedback loop. Adapted from 
Saijo and Glass 2011, Garden and La Spada 2012. 
Besides pro-inflammatory cytokines, activated microglia produce and release high 
amounts of reactive oxygen and nitrogen species (ROS and RNS), proteases, and glutamate. The 
elevation of ROS/RNS levels is mainly due to the activation of reduced nicotinamide adenine 
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dinucleotide phosphate (NADPH) oxidase (NOX) and nitric oxide synthase (NOS) enzymes, 
respectively. The production of ROS and RNS is part of a cytotoxic attack against invading 
pathogens (Saijo and Glass 2011, Rojo, McBean et al. 2014). Furthermore, ROS and RNS are 
important second messengers. The transcription factor NF-κB, key player in activation of 
inflammatory associated genes, can be regulated by ROS. 
ROS and RNS production in microglia 
ROS are a group of reactive oxygen-derived molecules, such as: oxygen radicals, hydrogen 
peroxide, peroxynitrite, and nitric oxide (NO). ROS can induce oxidative modification of nucleic 
acids, sugars, lipids and proteins. Also, they play a role in intracellular signalling through the 
inactivation of specific enzymes (e.g. the inactivation of protein tyrosine phosphatases leads to 
increased tyrosine kinase activity). Several enzymes can generate intracellular ROS, such as: 
Xanthine oxidase, cyclooxygenases, NOS, mitochondrial oxidases, and NOXes (Heyworth, Knaus et 
al. 1993). In microglia, as well as in others cells types, incomplete reduction of molecular oxygen 
in mitochondrial respiration generates ROS that are important for several cellular functions. 
However, one of the most important source of ROS in microglia is activation of NOX (Block and 
Hong 2005). NOX is a multi-subunit enzyme complex which activity results in the generation of 
superoxide anion as primary product by transferring electrons from NADPH to molecular oxygen. 
In normal conditions, some complex subunits are in the cytosol (p40phox, p47phox, and p67phox) 
and others are in the cell membrane (p22phox and gp91phox) (Heyworth, Knaus et al. 1993, 
Cheng, Diebold et al. 2006, McCann and Roulston 2013). Upon stimulation, the complex is 
assembled in the plasma membrane and becomes catalytically active. NOX can be activated in 
response to growth factors or inflammatory cytokines that signal through the Rho-like small 
GTPases Rac1 or Rac2 (fig.3) (Cheng, Diebold et al. 2006, McCann and Roulston 2013). ROS 
generated by NOX act on surrounding cells and constitute a cytotoxic attack. Further, ROS 
generated by NOX play an important role in modulating microglia function, including the release 
of neurotransmitters and production of pro-inflammatory cytokines (Giudice, Arra et al. 2010). 
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Figure 3 – Schematic representation of NADPH oxidase in resting and activated conditions. In resting conditions, 
NADPH oxidase is inactive and some complex subunits are in the cytosol (p40phox, p47phox, and p67phox) while others 
are in the cell membrane (p22
phox
 and gp91
phox
). Rac is stabilized in cytosol by Rho GDP-dissociation inhibitor (RhoGDI) 
which prevents nucleotide exchange and membrane association. Upon stimulation by inflammatory mediators, the 
complex is assembled in the plasma membrane, becoming activated. After activation, p47phox becomes 
phosphorylated triggering conformational changes that result in its translocation to the membrane and assembly to 
p22phox and gp91phox complex (known as flavocytochrome). Furthermore, cell activation leads to activation of 
guanine nucleotide exchange factors (GEFs, not represented), causing exchange of GDP for GTP in Rac and its 
consequent activation and translocation to the membrane. Activated Rac binds to the flavocytochrome. When 
assembled, NOX generate superoxide (O
2−
) by transferring electrons (2e
-
) from NADPH to molecular oxygen (2O
2
). 
Adapted from McCann and Roulston 2013. 
As mentioned before, one of the outcomes of activated microglia is the production of NO. 
In general, NO can be synthetized by tree isoforms of NOS: NOS1 (or neuronal NOS); NOS2 
(inducible NOS – iNOS) and NOS3 (endothelial NOS). NOS 1 and NOS3 are constitutively expressed 
and become activated upon increase of intracellular Ca2+ (Brown 2010). On the other hand, iNOS 
is transcriptionally induced by inflammatory mediators (e.g. LPS, TNF, IL-1β) and its activation is 
independent of the increase in intracellular Ca2+ (Murphy 2000). In microglia, the main source of 
NO is iNOS, which is synthetized from L-Arginine. Nitric oxide and L-citrulline are generated from 
L-arginine, in the presence of oxygen, NADPH, as well as the following co-factors: flavin 
mononucleotide (FMN), flavin adenine dinucleotide (FAD), haem and tetrahydrobiopterin (BH4) 
(Rojo, McBean et al. 2014). At low concentrations, NO is important in CNS physiology and 
participates in neurotransmission and cognition (Calabrese, Mancuso et al. 2007), while high 
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concentrations of NO are cytotoxic and may cause neuronal death by energy depletion mediated-
necrosis, or by nitrosative stress mediated-apoptosis (Brown and Cooper 1994, Brown 2010). 
Nuclear factor-kappa B  
NF-κB consists of a family of transcription factors that play critical roles in inflammatory 
responses and environmental and cellular damage (Rojo, McBean et al. 2014). In mammals, the 
NF-κB family consists of five proteins: NF-κB1 (p50), NF-κB2 (p52), RelA (p65), RelB, and c-Rel. 
These proteins have 300 amino acid long amino-terminal Rel homology domain (RHD) 
(Oeckinghaus and Ghosh 2009). This conserved sequence is required for dimerization, binding to 
DNA, interaction with inhibitors of NF-κB proteins (IκBs) and nuclear translocation. The 
association of different dimers leads to different signals mediated through NF-κB. The p65/p50 
dimer is the most well characterized in microglia and it is able to activate pro-inflammatory genes 
(Rojo, McBean et al. 2014). 
In normal conditions, NF-κB dimers remain inactive in the cytosol through interaction with 
IκBs. Degradation of IκBs is induced by IκB kinase (IKK) phosphorylation. This phosphorylation 
targets IκB for ubiquitin/proteasome degradation, and consequent NF-κB stabilization and 
translocation to the nucleus (fig. 4). NF-κB translocation to the nucleus induces the transcription 
of many target genes, for instance, cytokines (e.g. TNF; IL-1β, IL-6), chemokines (C-X-C motif) 
ligand 1, 2 and 10 (CXCL1, CXCL2 and CXCL10), adhesion molecules (e.g vascular cell adhesion 
molecule 1 (VCAM1), intercellular adhesion molecule 1 (ICAM1) and enzymes (e.g. iNOS) 
(Oeckinghaus and Ghosh 2009, Rojo, McBean et al. 2014). Although NF-κB activity is inducible in 
most cells, it can be constitutively active in some cell types, such as macrophages and neurons 
(Oeckinghaus and Ghosh 2009). 
ROS can regulate NF-κB activity by different mechanisms, for example, ROS can activate 
IKK (e.g. IKKβ) leading to phosphorylation of specific serines in IκB. This phosphorylation targets 
IκB for ubiquitin/proteasome degradation, and consequent NF-κB stabilization and translocation 
to the nucleus (Rojo, McBean et al. 2014). 
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Figure 4 – Canonical activation pathway of NF-κB. In normal conditions, NF-κB dimers remain inactive in cytosol trough 
interaction with IκBs (e.g IkR). However, when stimulated (e.g through TNF; IL-1; LPS) there is activation of IκB kinase 
(constituted by two catalytically active kinases, IKKa and IKKb, and the regulatory subunit -NEMO) which phosphorylates 
IκB and leads to its ubiquitination and proteasomal degradation. As a consequence, free p50/p65 is translocated to 
nucleus where it can activate the transcription of target genes. Adapted from Oeckinghaus and Ghosh 2009. IκBs: 
Inhibitor of NF-κB; TNF: Tumor necrosis factor; IL-1:Interleukine 1; LPS: lipopolysaccharide; NEMO:NF-kappa-B essential 
modulator. 
Glutamate release 
Glutamate is an excitatory neurotransmitter released by microglia that induces 
excitotoxicity and may contribute to neuronal damage in neurodegenerative diseases. Glutamate 
can be released from microglia by different mechanisms, one of which is the increased expression 
and/or activity of the cystine/glutamate antiporter xc- (Kettenmann, Hanisch et al. 2011). This 
transporter exchanges glutamate for cystine according to the respective concentration gradients. 
In activated microglial cells increased activation of this exchanger is associated to high demand for 
Canonical pathway 
(TNF, IL-1, LPS) 
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cystine/cysteine. Cystine is required for the synthesis of glutathione, the major antioxidant 
molecule in microglia, which is rapidly consumed in activated microglia due to increased oxidizing 
conditions (Kettenmann, Hanisch et al. 2011, Rojo, McBean et al. 2014). As a consequence, the 
release of glutamate can induce neuronal loss and toxicity to other CNS cells by either 
overstimulation of glutamate receptors or by reversing xc- (Kumar, Singh et al. 2010). Another 
mechanism for glutamate release is mediated by TNF. This cytokine induces extensive glutamate 
release from microglia in an autocrine fashion by up-regulating glutaminase, an enzyme that 
generates glutamate from glutamine. Such TNF-induced glutamate release occurs mainly through 
the connexin-32 hemichannel (Takeuchi, Jin et al. 2006). 
1.1.3.3.  Alternative anti-inflammatory signature  
The pro-inflammatory activation of microglia is often followed by the acquisition of an 
alternative activation phenotype in which microglia assume a neuroprotective profile with 
increased phagocytic capacity and production and release of high amounts of anti-inflammatory 
cytokines such as TGF-β and IL-10 (Ransohoff and Perry 2009, Kettenmann, Hanisch et al. 2011, 
Rojo, McBean et al. 2014). After a pro-inflammatory response, both ROS and RNS amounts must 
be lowered. In order to achieve that, microglia activate the transcription factor nuclear factor 
erythroid 2–related factor 2 (NRF2), which is considered the master modulator of redox 
homeostasis (fig.5) (Rojo, McBean et al. 2014). Moreover, anti-inflammatory phenotype is 
characterized by expression of wound healing genes, such as genes coding for arginase-1, 
scavenger receptors, neurotrophins and growth factors. This response is crucial for recovering 
homeostasis and to turn off the pro-inflammatory phenotype in microglia (Rojo, McBean et al. 
2014) 
Arginase-1 expression and activity  
Microglia anti-inflammatory phenotype is associated to the expression and activity of 
arginase-1. Arginase-1 is an enzyme that uses L-arginine, the same substrate used by iNOS, to 
generate ornithine. Since both enzymes compete by the same subtract, arginase-1 is considered 
an important regulator of NO production. In the anti-inflammatory phenotype, iNOS expression is 
decreased and arginase-1 expression can be induced by IL-4 and IL-13, for example. On the 
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contrary, in pro-inflammatory conditions, both iNOS expression and activity are up-regulated. 
(Rojo, McBean et al. 2014).  
 
 
 
 
 
 
 
 
 
 
 
 
 
NRF2 signalling pathway  
The transcription factor NRF2 plays an important role in antioxidant protection of 
microglial cells by enhancing the expression of cytoprotective genes (Rojo, McBean et al. 2014). 
For example, it has been demonstrated that the administration of LPS or MPTP (1-Methyl-4-
Figure 5 – Microglial cell phenotype is regulated by ROS through activation of NF-κB and NRF2. In homeostatic 
conditions, microglia present low levels of ROS/RNS, in a balance that is maintained by the antioxidant machinery of 
the cell. Upon pro-inflammatory stimulation, microglia increase ROS/RNS production, which function as a cytotoxic 
attack against pathogens or damaged cells. Also, ROS/RNS are involved in intracellular signalling cascades. NF-κB 
activity is induced by increased levels of ROS and leads to expression of pro-inflammatory mediators, resulting in 
more ROS/RNS production. After the pro-inflammatory response, NRF2 activity is increased in response to ROS/RNS in 
order to restore redox homeostasis, thus favouring an anti-inflammatory phenotype. Adapted from Rojo, McBean et 
al. 2014. NF-κB: Factor nuclear kappa B; NRF2: Nuclear factor erythroid 2–related factor 2; ROS: reactive oxygen 
species; RNS: reactive nitrogen species.   
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phenyl-1,2,3,6-tetrahydropyridine) results in enhanced microglial pro-inflammatory response in 
NRF2-null mice when compared to control animals. Moreover, the anti-inflammatory response is 
decreased in NFR2 deficient mice (Rojo, Innamorato et al. 2010).  
NRF2 controls the expression of genes encoding enzymes involved in ROS clearance (e.g. 
superoxide dismutase-3 - SOD3), synthesis of reducing factors (e.g. glutamate-cysteine ligase -
GCLC, which is involved in the generation of glutathione), production of antioxidant molecules 
(e.g. heme oxygenase, HO-1), and production of reduced cofactors and proteins (e.g. thioredoxin 
reductase 1 - TXNRD1) (Jung and Kwak 2010).  
In homeostatic conditions, NRF2 has a short half-life due to binding to a Cullin 3-specific 
adaptor protein (Keap1). Keap1 anchors NRF2 in the cytoplasm targeting it for ubiquitination and 
proteasomal degradation (Kensler, Wakabayashi et al. 2007, Giudice, Arra et al. 2010). Upon 
exposure to oxidative conditions, critical cysteine residues in Keap1 are oxidized and its ligase 
activity is inhibited. As a consequence, NFR2 escapes degradation and is translocated to the 
nucleus where it heterodimerizes with other transcription factors (e.g., sMaf, ATF4, JunD, PMF-1). 
Heterodimers are able to bind to cis-acting antioxidant response elements (ARE) located in the 
promoter region of target genes and induce their expression (fig.6). Moreover, NRF2 may be 
controlled by other mechanisms such as: signalling kinases regulated by ROS, or epigenetic 
mechanisms like acetylation, CpG island methylation of its promoter region and micro ribonucleic 
acid (miRNA) generation (Bryan, Olayanju et al. 2013, Rojo, McBean et al. 2014). 
  
Figure 6 - The Keap1-NRF2 system. Under homeostatic normal, Keap1 reduces the levels of NRF2 in cytosol by 
directing it to ubiquitination and proteasomal degradation. Upon oxidative or electrophilic stress, Keap1 becomes 
oxidized in critical cysteine residues and is inactivated. Free NRF2 is stabilized and translocated to nucleus, where it 
binds to antioxidant response elements (AREs) through heteromerizing with the small Maf protein and activates the 
expression of cytoprotective genes. Adapted from Mitsuishi, Motohashi et al. 2012. Keap1: Cullin 3-specific adaptor 
protein; NRF2: Nuclear factor erythroid 2–related factor 2. 
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Microglia phagocytosis  
Microglial cells are able to migrate toward the site of injury and phagocytose pathogens 
or damaged cells. In general terms, the process of phagocytosis implies the vesicular ingestion of 
extracellular particles. After antigen recognition, the cell extends protusions (pseudopodia) that 
surround the material. The pseudopods fusion encloses the material in a phagosome, entering the 
endocytic processing pathway. Inside the cell, phagosomes fuse with lysosomes, forming 
phagolysosomes where several enzymes hydrolyse the material. Digested contents are eliminated 
by exocytosis. The phagocytic process is highly dependent on rearrangements of the actin 
cytoskeleton triggered by environmental signals (Neumann, Kotter et al. 2009). 
Phagocytes have two different types of phagocytic receptors for antigen recognition: (i) 
receptors that recognize pathogens and trigger a pro-inflammatory response, such as TLRs that 
recognize PAMPs or Fc receptors that interact with opsonized antigens (Neumann, Kotter et al. 
2009); and (ii) receptors recognizing exposure of apoptotic material, including those that 
recognize phosphatidylserine (Neumann, Kotter et al. 2009). The latter are associated with an 
anti-inflammatory response. 
1.1.4. Microglia in neuroprotection versus neurodegeneration  
While microglia-mediated inflammation is crucial for tissue repair for the maintenance of 
healthy brain, their chronic activation or deregulation contributes to the pathophysiology of 
several neurodegenerative diseases. For instance, microglia activation has been reported in the 
brain and spinal cord of patients with Amyotrophic Lateral Sclerosis (ALS), a progressive 
neurodegenerative disease of motor neurons. Microglia activation in the asymptomatic phase of 
ALS might be beneficial by playing a protective role in the CNS. However, during disease 
progression, microglia activation becomes deleterious contributing to neuronal injury and loss 
(Boillee, Vande Velde et al. 2006). 
In chronic neuroinflammatory diseases (e.g. multiple sclerosis), microglial cells are 
constantly exposed to disease-related molecules or damaged cells that lead to chronic activation 
of microglia. As mentioned in previous sections, activated microglia release toxic compounds, 
increase phagocytic activity and activate an inflammatory response. Microglia activation induces 
pro-inflammatory phenotypes in other microglial cells, which might generate a net effect in 
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microglia population. A large pool of activated microglia releasing toxic factors (such as 
glutamate, ROS, RNS, TNF and proteases) leads to bystander damage to neurons and other CNS 
cells.  
Considering both pathologic and beneficial roles of microglia in the CNS, the simple 
inhibition of microglial cell-mediated inflammation would not contribute to a beneficial outcome. 
In order to define targets and develop appropriate therapeutic strategies to fight excessive 
inflammation mediated by microglia, it is essential to understand the mechanisms underlying the 
process of microglial cell activation.  
1.2.  Microglia and profilin 
Dong and colleagues suggested that profilin (Pfn), an actin-binding protein that regulates 
actin cytoskeleton polymerization and participates in other cellular process, might be involved in 
microglial activation (Dong, Ying et al. 2004). The authors used unilateral destruction of principal 
extrinsic input from the entorhinal cortex to the hippocampus to study microglia reactivity in rats. 
In this model, microglia activation is the first detectable response in the hippocampus of these 
rats. Microglia activation results in induction of a pro-inflammatory response and clearance of 
axonal debris by phagocytosis. In order to find genes associated with lesion-induced plasticity, the 
authors performed a cDNA microarray analysis and they found that Pfn was up-regulated upon 
lesion, which was further confirmed by Northern blot and in situ hybridization analysis. They also 
showed that Pfn expression was increased in microglial cells using the combination of in situ 
hybridization for Pfn messenger RNA with in vivo labelling for microglia using the Griffonia 
simplicifolia IB4 staining. The authors proposed that Pfn might modulate microglia activation via 
the regulation of the actin cytoskeleton. Asides from the study of Dong and colleagues, the role of 
Pfn in microglia function is elusive. 
1.3. Profilin-1 
Profilins (Pfns) are a class of evolutionarily conserved small actin-binding proteins (12-15 
kD) that regulate the dynamics of actin polymerization (Carlsson, Nystrom et al. 1977). Pfn1 is the 
founding member of the family and Carlsson and colleagues in 1976 were the first to describe its 
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expression in the calf spleen. Since then, Pfn expression was observed in many organisms, such as 
insects, plants and mammals (Jockusch, Murk et al. 2007). In mammals, there are four distinct 
genes encoding for Pnfs: Pfn1 codes for the ubiquitously expressed Pfn1; Pfn2 codes for two 
splicing variants, one of which is expressed only in developing nervous system and differentiated 
neurons (Pfn2a), and the other one being mainly found in kidney (Pfn2b); Pfn3 and Pfn4 code for 
Pfn3 and Pfn4, respectively, which are both restricted to testis (Witke 2004, Jockusch, Murk et al. 
2007). 
Although Pfns are highly conserved in evolution, its sequence homology is low. Secondary 
and tertiary structures, on the other hand, are very similar throughout species and family 
members, suggesting that conformation is more important to function than amino acid sequence. 
Mammalian Pfns have a compact center consisting of seven beta sheets, surrounded by four 
alpha helices. The N- and C-terminal domains are adjacent to each other (Schutt, Myslik et al. 
1993, Fedorov, Magnus et al. 1994, Domke, Federau et al. 1997). The structure of Pfn1 is 
represented schematically in fig.7. 
In general, Pfns bind to three main classes of ligands: actin, proteins containing poly-L-
proline (PLP) motifs and phosphoinositides, with preference for phosphatidylinositide-4,5-
bisphophate (PIP2) (fig.7). The actin-binding site of Pfn1 do not enclose the N- and C- terminal in 
the folded molecule (Schutt, Myslik et al. 1993) (fig.7). Besides the potential to interact with actin, 
this Pfn1 domain also interacts with actin-related proteins (ARPs), such as ARP2 and ARP3. 
Pfn1 interacts with proteins containing PLP motifs: 3-5 prolines residues flanked by a 
glycine or a alanine residue (Ding, Bae et al. 2012). The PLP interaction domain involves both the 
N- and C-terminal domains of Pfn1 (fig.7), not interfering with actin binding site. The vasodilator 
stimulated phosphoprotein (VASP) was the first ligand identified for Pfn1’s PLP binding site 
(Reinhard, Giehl et al. 1995). Since then, several ligands have been identified, with variable 
function, structural organization and cellular location. Pfn1 can interact with important proteins 
for actin dynamics and organization, signal perception, motility, storage, transport and 
transcription (Jockusch, Murk et al. 2007, Ding, Bae et al. 2012).  
Pfn1 also interacts with phosphatidylinositides with preference for PIP2 (Lassing and 
Lindberg 1985). PIP2 binding site overlaps with both actin and PLP binding sites (fig. 7). Hence, 
there is a competition between PIP2 and actin binding for Pfn, as well as between PIP2 and PLP 
(Ding, Bae et al. 2012). PIP2 binds not only to Pfn, but also to Pfn1-actin complexes, which leads to 
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complex dissociation. Furthermore, PIP2-Pfn interaction has the potential to interfere with several 
intracellular signalling cascades, since this interaction inhibits the hydrolysis of PIP2 by 
phospholipase C (PLC), and consequently the formation of the second messengers: Diacylglycerol 
(DAG) and inositol 1,4,5-trisphosphate (IP3). DAG activates protein kinase C, which activates other 
cytosolic proteins by phosphorylation, while IP3 activates IP3 receptors in the endoplasmic 
reticulum, inducing calcium release to the cytosol, which, in turn, participates in other signalling 
pathways. PIP2 bounded to Pfn1 can only be hydrolysed into second messengers by 
phosphorylated PLCγ1 (Goldschmidt-Clermont, Kim et al. 1991) (fig.8). 
Actin-binding domain 
PLP-binding domain 
PIP2-binding domain 
Figure 7 -  Schematic representation of a profilin tertiary structure. Actin-binding domain is represented in red; PLP-
binding domain in blue and PIP2-binding domain in green. Adapted from Jockusch, Murk et al. 2007. PIP2: 
phosphatidylinositide-4,5-bisphophate. PLP: Poly-L-proline. 
Figure 8 - Schematic representation of Pfn1 and PIP2 interaction. Pfn1 binds to phosphatidylinositides with preference 
for PIP2. PIP2 bounded to Pfn1 can only be hydrolysed by PLCγ1. PIP2 hydrolysis in DAG (diacylglycerol) and IP3 (inositol 
1,4,5-trisphosphate) leads to Pfn1 release. In cytosol Pfn1 binds to ADP-actin and catalyses the exchange of ADP for 
ATP. IP3 is a second messenger and participates in intracellular signalling cascades. 
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1.3.1. Profilin and actin dynamics 
1.3.1.1. Actin cytoskeleton  
The actin cytoskeleton is a highly dynamic network composed of microfilaments (polymers 
of actin) and a large number of actin-binding proteins (Schmidt and Hall 1998). Classical functions 
of the actin cytoskeleton are to mediate cell shape changes, surface remodelling and motility. 
Moreover, the actin cytoskeleton is involved in cell-cell and cell-substrate interactions, in 
transmembrane signalling, endocytosis and secretion (Schmidt and Hall 1998, Le Clainche and 
Carlier 2008).  
Actin exists in both as monomeric (G-actin) and polymeric (F-actin) form. The dynamic of 
the actin cytoskeleton is regulated by the balance between these two forms, in response to 
external stimuli (Schmidt and Hall 1998, Le Clainche and Carlier 2008, Lee and Dominguez 2010). 
Actin polymerization takes place at the barbed end of the filaments, while at the point end 
depolymerisation occurs (fig. 9). Actin cytoskeleton assembly is regulated at several levels, 
including the organization of monomers in polymers and the organization of filaments into a 
network. This regulation is dependent on multiple actin binding proteins that assume a wide 
range of functions, including: actin filament nucleation (formation of the initial 3 actin monomers 
complex), elongation (polymerization), severing (depolymerizing), capping (prevents adding or 
loss of actin subunits) and crosslinking (superorganization of actin polymers into a filamentous 
network) (Jockusch, Murk et al. 2007).  
Moreover, the assembly and disassembly of the actin cytoskeleton are tightly regulated, 
thus divergent signalling pathways target diverse actin-associated proteins. The Rho family of 
small GTPases are key players in the actin cytoskeleton dynamics. They regulate signalling 
pathways linking the assembly and organization of either actin or microtubule cytoskeleton with 
external and internal signals. Among other Rho GTPases, RhoA, Rac1 and Cdc42 have been 
extensively characterized. Concerning the regulation of the actin cytoskeleton, RhoA is well 
known for mediating the formation of stress fibers (bundles of actin filaments that traverse the 
cell and reaches out focal adhesions), Rac1 induces lamellipodia (extensions of flat protusions) 
formation and Cdc42 promotes arrangement of filopodia (fingerlike protusions) (Schmidt and Hall 
1998, Stankiewicz and Linseman 2014). 
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1.3.1.2. Profilin 1 
Among other proteins, Pfn1 assumes an important role in regulating actin polymerization. 
Pfn1 forms 1:1 complexes with monomeric actin (Carlsson, Nystrom et al. 1977) and, by catalysing 
the exchange of ADP for ATP in actin, provides a pool of ATP-bounded monomers, which can be 
incorporated in free barbed ends of actin filaments (fig.9).  
Furthermore, Pfn1 is important for de novo actin nucleation and elongation of new or pre-
existing filaments, processes that are involved in membrane protrusion that is required for cell 
motility (fig. 10). Pfn1 is able to interact directly with N-WASP/WAVE, Ena/VASP and formins 
through the PLP binding domain. Members of Ena/VASP, formin and WASP/WAVE families are the 
majors catalysers of actin nucleation and elongation. Those are large multidomain proteins that 
are able to bind Pfn, G- and F-actin. The PLP stretches exposed in Ena/VASP, formin and 
WASP/WAVE members are able to interact with several Pfn-actin complexes simultaneously, 
promoting their polymerization (Jockusch, Murk et al. 2007). 
 
Figure 9 – Actin polymerization process.  (1) Actin depolymerizing factor (ADF) induces actin depolymerisation at 
pointed end. (2) Profilin interacts with actin and catalyses the exchange of ADP for ATP, providing a pool of ATP-
actin that can be rapidly incorporated at actin filament free barbed end. (3) Capping proteins block the majority of 
barbed ends. Adapted from Le Clainche and Carlier 2008. ATP Adenosine triphosphate; ADP: adenosine 
diphosphate. 
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1.3.2. Profilin and membrane trafficking 
Pfns are involved in endocytosis and membrane trafficking, as suggested by the presence 
of Pfn1 at budding Golgi vesicles and the existence of a Pfn1-dependent recruitment of dynamin 2 
to the Golgi (Dong, Radau et al. 2000). Furthermore, the interaction between Pfn2 and dynamin 1 
is better characterized in the mouse brain (Gareus, Di Nardo et al. 2006). Overexpression of Pfn2 
inhibits endocytosis by sequestering dynamin 1, the central regulator of endocytosis in neurons, 
thus preventing dynamin interaction with other effector molecules.  
1.3.3. Nuclear profilin  
Due to their globular structure and small size Pfn (15 kDa) and Pfn-actin (57 kDa) are able 
to enter in the nucleus by diffusion. However, there is a specific export system to remove profilin-
actin from the nucleus, the exportin 6 (Stuven, Hartmann et al. 2003).  
Despite the fact the functions of Pfn and its ligands in the nucleus are less understood, 
studies suggest that Pfn might have a role in mRNA splicing and maturation, since (i) anti-Pfn1 
antibodies interfere with mRNA splicing in vitro; (ii) Pfn interacts with proteins involved in those 
processes (Survival motor neuron –SMN; and p80 coilin) and (iii) immunolocalization studies show 
the presence of Pfn1 in splicing speckels and Cajal bodies (Skare, Kreivi et al. 2003). Besides, some 
studies suggest a role for Pfn in regulating gene expression in neuronal cells (Lederer, Jockusch et 
al. 2005). In this study, the authors showed that Pfn1 interacts and regulates p42POP that is a 
transcriptional modulator, suggesting that Pfn1 might participate in transcriptional regulation.  
1.3.4. Profilin 1 regulation 
As mentioned before, Pfn1 interaction with PIP2 functions as a link through which the 
signalling pathways communicate with the dynamics of the actin cytoskeleton. Previously, it has 
been reported in vitro that Pfn1-PIP2 binding can inhibit hydrolysis mediated by phospholipase-Cγ 
(PLCγ) (Goldschmidt-Clermont, Machesky et al. 1990). However, the phosphorylation of 
phospholipase C-gamma 1(PLCγ1) can overcome the inhibitory effect of Pfn1 binding 
(Goldschmidt-Clermont, Kim et al. 1991). PLCγ becomes phosphorylated in response to external 
stimuli, for instance by the epidermal growth factor receptor tyrosine kinase. Upon hydrolysis, 
Pfn1 is released in the cytoplasm where it can execute its function. Pfn1 binding to PIP2, or PIP to 
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Figure 10 - Schematic representation of Pfn1 actin-associated functions. (1) Pfn1 interacts with PIP2 regulating Pfn1 
availability in cytosol. (2) Phosphorylated PLCγ1 is able to hydrolyse PIP2. In consequence, Pfn1 is released for cytoplasm 
where it can execute its function. (3) Free Pfn1 binds to G-actin and catalyses the exchange of ADP for ATP, providing a 
pool of monomers that can be rapidly polymerized. (4) The profilin-ATP-G-actin complex can be added to nascent actin 
filaments. Pfn1 is important for de novo actin nucleation and elongation of new or pre-existing filaments through 
interaction with several mediators with PLP stretches. Adapted from Jockusch, Murk et al. 2007. PIP2: 
phosphatidylinositide-4,5-bisphophate; PLCγ1: Phospholipase Cγ1;  ATP Adenosine triphosphate; ADP: adenosine 
diphosphate. 
a lesser extent to PIP, compromise PIP2 availability in the membrane, interfering with intracellular 
signalling cascades. For instances, there are studies in cancer cells reporting that PI3K/AKT 
pathway is sensitive to perturbations in Pfn1  expression (Das, Bae et al. 2009, Jin, Song et al. 
2012).  
Post-transcriptional modifications of Pfn1 can alter its proprieties and function. In HEK293 
cells and primary neurons, the Rho associated coil-coil kinase (ROCK) phosphorylates Pfn1 at 
serine residue 137, leading to Pfn1 inactivation and concomitant impairment of actin binding 
activity (Shao, Welch et al. 2008). On the other hand, phosphorylation of Pfn-1 at tyrosine 129 by 
chemotactic activation of VEGF receptor kinase-2 (VEGFR2) and Src promotes Pfn-1 binding to 
actin and actin polymerization in endothelial cells (Sathish, Padma et al. 2004).  
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1.3.5. Profilin 1 in vivo 
Several studies have demonstrated that deletion of Pfn1 is incompatible with life. Pfn1 
deletion in mice leads to embryonic lethality before implantation probably due to defects in 
cytokinesis, indicating a critical role for Pfn1 in initial stages of mouse development (Witke, 
Sutherland et al. 2001). Heterozygous mice for Pfn1 are viable, but present alteration in brain 
morphology and have reduced survival and Pfn2 presence in brain does not compensate for Pfn1 
loss. In contrast, Pfn2 deficient mice are viable and the overall brain morphology is apparently 
normal, although these mice show behavioural abnormalities (Pilo Boyl, Di Nardo et al. 2007).  
Pfns have been implicated in many pathological conditions, such as allergies, 
cardiovascular diseases, muscular atrophy, diabetes, dementia and cancer.  Regarding cancer, 
Pfn1 has been considered a tumor-suppressor since its protein expression is constitutively 
downregulated in breast and other cancer cell lines (Janke, Schluter et al. 2000). In addition to 
promoting actin polymerization, membrane protrusion and motility, Pfn1 reduction has been 
shown to enhance motility and invasion in several tumor cells (Zou, Jaramillo et al. 2007). On the 
other hand, Pfn1 overexpression leads to the formation stress-fibers, increases focal adhesion, 
promotes cell spreading and impairs motility and invasion (Janke, Schluter et al. 2000).  
Pfn1 has also been implicated in many neurodegenerative diseases. For example, Pfn1 
interacts with huntingtin, the protein mutated in Huntington disease. Mutant huntingtin leads to 
downregulation of Pfn protein in Drosophila eye. Disease phenotype can be restored by 
increasing Pfn1 expression (Shao, Welch et al. 2008). A recent study also showed that missense 
mutations in the human PFN1 gene are linked to familial amyotrophic lateral sclerosis (ALS) (Wu, 
Fallini et al. 2012). 
1.4. Aims 
The main goal of this work was to dissect the role of Pfn1 in microglia cell function. In 
particular, we were interested in determining: (i) Pfn1 expression and phosphorylation in 
activated microglia, (ii) the impact of Pfn1 reduction in anti- and pro-inflammatory mediators, and 
(iii) the role of Pfn1 in microglia ROS production.  
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2. Experimental procedures 
2.1. Reagents 
Hank's Balanced Salt Solution 1x (HBSS), Penicillin Streptomycin (Pen/Strep), DMEM (1x) + 
Glutamax TM-I, trypsin-EDTA (Trypsin-Ethylenediamine tetra-acetic acid), DMEM/F12 and 
CellROX® Deep Red Reagent were acquired from Life Technologies. FBS (Fetal bovine serum), 
poly-D-lysine, latex beads, protease, phosphatase and TRI reagent were acquired from Sigma-
Aldrich. Lysogeny broth-agar (LB-agar) and bovine serum albumin (BSA) acquired from NZYtech. 
Super Optimal Broth media and NucBusterTM Protein Extraction Kit were acquired from Novagen. 
NucleoBond® Xtra plasmid purification was acquired from MACHEREY-NAGEL. iQ™ SYBR® Green 
Supermix and transference buffer Trans Blot Turbo were acquired from BioRad. jetPrime®was 
acquired from Polyplus transfectionTM; Puromycin from Calbiochem; Triton X-100 from VWR; 
Direct-zol™ RNA MiniPrep from Zymo Research; SuperScript™ III First-Strand Synthesis SuperMix 
for qRT-PCR  from Invitrogen; GoTaq® Green Master Mix from Promega and Pierce™ BCA Protein 
Assay Kit fromThermo Scientific). 
2.2. Animals  
All animal experiments were performed according to European Union and National 
guidelines and approved by Animal Ethics Committee of the Institute for Molecular and Cell 
Biology (IBMC) and Portuguese Veterinarian Board. Animals were housed at IBMC facility under 
controlled temperature and light conditions (12 hours light/12 hours dark cycles) with water and 
standard rodent food ad libitum. To perform mixed glial cultures, Wistar rats were sacrificed by 
decapitation at P1-P2. P60 mouse expressing an IRES-EYFP (internal ribosome entry site-enhanced 
yellow fluorescent protein) under the control of CX3CR1 promoter was used to show the 
expression of Pfn1 in microglia in vivo (Parkhurst, Yang et al. 2013). 
After being anesthetized with pentobarbital, CX3CR1-EYFP mouse was perfused with 
phosphate-buffered saline (PBS) followed by 4% paraformaldehyde (PFA). Brains were collected 
and post fixed at 4°C overnight. Tissues were subjected to sucrose gradient (15% and 30% 
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sucrose) for cryopreservation and sectioned at 20 µm in a cryostat (Leica). Sagittal sections were 
collected in Superfrost glass-slides (Thermo Scientific) for immunohistochemistry. 
2.3. Cell culture 
2.3.1. Mixed glial cell cultures 
Wistar rat litters (6-15) were sacrificed by decapitation at P1-P2, cerebral cortices and 
hippocampus were dissected and placed in cold HBSS with 1% Pen/Strep. After removing the 
meninges, tissues were incubated with 0.0025% Trypsin-EDTA and 50μg/mL DNase for 10 minutes 
at 37°C. The trypsinization was terminated with 12mL of DMEM (1x) + GlutamaxTM-I 
supplemented with 10% FBS + 1% Pen/Strep. Samples were centrifuged at 200g for 7 minutes. 
The supernatant was discarded and the pellet was resuspended and homogenized in 20mL 
medium. Cell suspension was filtered through a 100µm cell strainer and distributed by 75cm2 
culture flasks previously coated with poly-D-lysine (10 µg/mL) (at approximately 2 pups/flask). The 
mixed glial cell cultures were maintained at 37°C in a humidified atmosphere with 5% CO2 for 10 
days and the medium was changed twice a week. Each mixed glia cell culture was subjected to 
tree shakes (with seven days interval) to obtain purified microglia cell cultures. 
2.3.2. Purified microglia cell cultures 
After 10 days in culture, microglial cells were visually identifiable in mixed glial cell 
cultures as the smallest and brightest cells in culture. Mixed glial cell cultures were subjected to 
orbital shaking (200 rotations per minute (rpm)) for 2 hours at 37°C. The medium enriched in 
microglia was collected and the cells were pelleted by centrifugation (200g for 10 minutes). After 
discarding the supernatant, the pellet was resuspended in DMEM/F12-GlutamaxTM-I 
supplemented with 10% FBS + 1% Pen/Strep and the cells were counted using a hemocytometer. 
Cells were seeded at 1 x 105 cells per mL on 12-well tissue culture plates with glass coverslips or 35 
mm2 dishes, or at 2 × 105 cells per mL in 100mm dishes (all surfaces were previously coated with 
poly-D-lysine). On the following day, culture medium was replaced. Cells were maintained at 37°C 
in a humidified atmosphere with 5% CO2. Previous tests in our laboratory demonstrated that this 
method provides cultures that reach 99% purity (Socodato, Portugal et al. 2015). 
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2.3.3. Microglial cell lines 
BV-2 microglial cells were kindly supplied by Dr. Francisco Ambrósio (University of 
Coimbra, Coimbra, Portugal). This cell line was derived from murine newborn animals (C57BL/6 
strain) and immortalized by transformation with the v-raf and v-myc oncogenes of the J2 
retrovirus (Blasi, Barluzzi et al. 1990). This cell line is often used as a substitute for primary 
microglia, as several studies demonstrated that BV-2 is similar to primary microglia function 
(Bocchini, Mazzolla et al. 1992, Guzy, Hoyos et al. 2005, Lund, Christensen et al. 2006, Henn, Lund 
et al. 2009). 
The human microglial cell line CHME3 was kindly supplied by Dr. Dora Brites, (University 
of Lisbon, Lisbon, Portugal). This cell line was derived from human fetal microglia immortalized 
with SV-40 large T-antigen (Janabi, Peudenier et al. 1995). CHME3 line is often used as a 
substitute for primary microglia (Green, Elkington et al. 2010, Hjorth, Frenkel et al. 2010).  
BV-2 and CHME3 were cultivated with DMEM (1x) + GlutamaxTM-I supplemented with 10% 
FBS + 1% Pen/Strep. Cells were maintained at 37°C in a humidified atmosphere with 5% CO2. Both 
cell lines were used to generate microglia Pfn1 knocked down stable cell sub-clones, as described 
in a subsequent section. BV-2 cells were employed for western blotting experiments due to their 
fast proliferation rate, while CHME3 cells were used for Förster resonance energy transfer (FRET) 
experiments, since those cells express the FRET biosensor with very high signal-to-noise ratio. 
2.4. Bacteria transformation and plasmid DNA 
purification 
Competent bacteria were incubated with 3,3 µg of plasmid on ice for 5 minutes and heat-
shocked at 42°C for 30 seconds. Then, cultures were cooled on ice for 5 minutes and 300µL of 
Super Optimal Broth media was added. Transformed bacteria were incubated at 37°C with 
shaking for 1 hour. Positively transformed colonies were selected by plating on LB-agar with 
100µg/mL ampicillin (since the plasmid of interest had an antibiotic resistance cassette). Bacteria 
were allowed to grow overnight at 37°C. 
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A starter culture was firstly prepared based on single positive colony picked from agar 
plate. Bacteria were inoculated in 5mL of LB medium under selection with 100µg/mL ampicillin in 
order to guarantee plasmid propagation. Bacteria were allowed to grow for 8 hours at 37°C with 
orbital shake (approximately 300 rpm). Then, a larger culture was prepared by diluting the starter 
culture in 150 mL of LB with 100µg/mL ampicillin. Bacteria were allowed to grow for 12-16 hours 
at 37°C with orbital shake. Afterwards, bacteria were harvest by centrifugation at 9000g for 10 
minutes at 4°C. Plasmid DNA was isolated and purified using NucleoBond® Xtra plasmid 
purification according to manufacturer’s instructions. Briefly, the bacterial pellet was resuspended 
with resuspension Buffer + RNase A and lysed with Lysis Buffer based on the NaOH / SDS lysis 
method. The whole lysate was loaded onto NucleoBond® Xtra Column together with 
NucleoBond® Xtra Column Filter where nucleic acids bind to the filter. The plasmid DNA was 
purified with wash buffer, eluted in elution buffer, precipitated with isopropanol, and 
resuspended in 400µL of nuclease-free water. Concentration of plasmid DNA was measured with 
NanoDrop spectrophotometer (Thermo Scientific) by optical density (OD) at 260nm wavelength 
and sample purity was determined using OD260/OD280 ratio. Plasmid DNA was stored at -20°C until 
use. 
2.5. Profilin 1 knockdown  
2.5.1. Lentivirus production 
The human HEK293T cell line (Human Embryonic Kidney 293 cells express SV40 large T 
antigen) was used for production of lentiviruses particles containing the plasmid encoding Pfn1 
small hairpin RNA (shRNA) (TRCN0000011972, Sigma) or the empty vector, pLKO. Low passage 
HEK293T cells were seeded in a 100mm2 plate with DMEM (1x) + Glutamax TM-I supplemented 
with 10% FBS and 1% Pen/Strep and maintained at 37°C in a humidified atmosphere with 5% CO2. 
When 80% of confluence was reached, cells were co-transfected using jetPrime® with the plasmid 
of interest together with packaging (psPAX2) and enveloping (PLP-VSVG) plasmids for the 
production of viral particles coding for the Pfn1 shRNA. Viral plasmids and the interested plasmid 
(Pfn1 shRNA or pLKO) were diluted in 500 µL of jetPRIME® buffer (4,2 µg psPAX2; 2,7 of  PLP-VSVG 
and 3,1 µg  plasmid Pfn1 shRNA) and thoroughly mixed. 20 µL of jetPRIME® was added to diluted 
DNA and, after vortexing for 10 seconds, the transfection mix was incubated for 10 minutes at 
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room temperature. Afterwards, the mix was added drop wise to the cells and the plate was gently 
rocked to ensure distribution of transfection mix. The transfection medium was replaced by fresh 
medium 4 hours after transfection. At 48 hours post-transfection, the medium containing viral 
particles was recovered by centrifugation at 1811g for 15 minutes at 4°C. Lentiviruses were stored 
at ‐80°C until use. 
2.5.2. Profilin 1 knockdown   
Primary microglial cells were infected 24 hours after plating with lentiviruses carrying 
Pfn1 shRNA or empty vector (pLKO). For infection, the culture medium was removed and the virus 
was added drop wise to the cells. Then, microglia growth medium was added and the plates were 
gently rocked to ensure distribution of viral supernatant. In all experiments, a proportion of 1:4 
(lentivirus: culture medium) was used. Cells remained in culture for 72 hours following infection. 
Pfn1 knockdown was confirmed by immunofluorescence and qRT-PCR analyses (in primary 
microglia) and western blotting (in BV-2 microglia). 
2.5.3. Microglia stable cell sub-clones 
In order to generate BV-2 and CHME3 stable lines, cells were infected with lentiviruses 
carrying Pfn1 shRNA or empty plasmid (1:1 lentivirus and medium) and allowed to grow for 48 
hours. Then, infected cells were selected with puromycin (6µg/mL) for 48 hours. The selection 
process was finished when non-infected control cultures were completely eliminated by 
puromycin. When necessary, a second round of puromycin treatment was performed. Stable cell 
sub-clones were maintained in culture with 2 µg/mL of puromycin prior to experiments. 
2.6. Phagocytosis efficiency assay 
Phagocytic efficiency assay was performed using fluorescent 0.5µm latex beads (L5530). 
Primary microglia were incubated with beads, previously resuspended in culture medium (1:1000 
(v/v)), for 45 minutes at 37°C. Then, cells were washed twice in PBS and fixed in 4% PFA in 
microtubule protection buffer (MP buffer; 65mM PIPES, 25mM HEPES, 10mM EGTA, 3mM MgCl2; 
pH 6.9) for 12 minutes. Microglia cells were immunostained with ionized calcium-binding adapter 
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molecule 1 (Iba-1) as described in section 3.8. Image acquisition was performed in a Leica 
DMI6000B inverted microscope. The protocol for calculating phagocytic efficiency was adapted 
from Koenigsknecht and colleagues (Koenigsknecht and Landreth 2004). In brief, the number of 
beads inside each cell was counted in Fiji software using an automated algorithm. For each cell, a 
score was assigned depending on the number of phagocytosed particles. Attributed scores and 
the corresponding range of phagocytosed beads are represented in table 1. Phagocytosis 
efficiency was calculated based on weighted arithmetic mean of phagocytosed beads per cell, 
using the following equation: 
?̅? =
(𝑛º 𝑐𝑒𝑙𝑙𝑠 𝑖𝑛 𝑠𝑐𝑜𝑟𝑒 1 × 1) + (𝑛º 𝑐𝑒𝑙𝑙𝑠 𝑖𝑛 𝑠𝑐𝑜𝑟𝑒 2 × 2) + ⋯ + (𝑛º 𝑐𝑒𝑙𝑙𝑠 𝑖𝑛 𝑠𝑐𝑜𝑟𝑒 6 × 6)
𝑇𝑜𝑡𝑎𝑙 𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑐𝑒𝑙𝑙𝑠
 
 
Table 1 – List of scores attributed to cells considering the number of particles phagocytosed. 
 
 
 
 
 
2.7. ROS production assay 
In order to evaluate ROS production, primary microglial cells were incubated with the 
fluorogenic probe CellROX® Deep Red Reagent. CellROX® is a cell-permeant dye that emits 
fluorescence upon oxidation by ROS. Cells were incubated with CellROX® at a final concentration 
of 5µM for 30 minutes at 37°C. Afterwards, cells were washed twice in PBS and fixed in 4% MP-
PFA for 12 minutes. Coverslips were mounted on glass-slides with Shandon ImmuMount 
(ThermoScientific). Image acquisition was performed in a Leica DMI6000B inverted microscope. 
Phagocytosed Beads Score 
1 - 7 1 
8 - 14 2 
15 - 21 3 
22 - 28 4 
28 - 35 5 
+ 36 beads 6 
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2.8. Anoxic and hypoxic challenge 
For western blot, BV-2 cells were plated in 100 mm2 dishes. Anoxia experiment was 
performed when cells reached 70% confluence. Before treatment, culture medium was replaced 
with fresh medium. Cells were exposed to anoxia by placing them in a chamber filled with a gas 
mixture of 95% N2 + 5% CO2 for 4 hours at 37°C. Control cells remained in the cell incubator under 
normoxia. After anoxia, cells were washed twice with PBS and protein extracts were performed.  
For FRET experiments, hypoxia was performed in the IBIDI micro-chamber coupled to 
Leica DMI6000B inverted microscope. Hypoxia conditions were reached by decreasing O2 levels to 
2%. During the time-lapse humidity (85%) and temperature (37°C) were controlled. With this 
approach, we studied the same cell both in normoxic and hypoxic conditions. 
2.9. Overexpression of Profilin 1 mutants in microglia 
cell line 
Plasmids encoding Pfn1 mutants were kindly supplied by Dr. Mónica Sousa (Institute for 
Molecular and Cell Biology - IBMC, Oporto, Portugal). Mutant Pfn1 plasmids were generated by 
site-directed mutagenesis: Pfn1R74E - actin binding domain defective Pfn1; Pfn1H133S - PLP binding 
domain defective Pfn1; Pfn1 S137D – phospho-mimetic Pfn1. Overexpression of Pfn1 mutants was 
performed in CHME3 microglia cell line. CHME3 cells were co-transfected with plasmids for Pfn1 
mutants (500ng) and ROS FRET probes (500ng) as described in section 3.13.1. The co-transfection 
with Pfn1 wild type (Addgene, clone IRATp970C034D) and ROS FRET probe was used as control. 
FRET experiment was performed 24 hours after transfection. Western blot for total Pfn1 was 
done to confirm the overexpression of Pfn1 24 hours after transfection. 
2.10. Immunofluorescence  
Coverslips containing purified microglia cell cultures were washed twice with PBS and 
fixed with 4% MP-PFA for 12 minutes. After washing, microglial cells were permeabilized with 
0.25% Triton X-100 in PBS for 10 minutes. Unspecific epitopes were blocked with 3% BSA in PBS 
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for 1 hour. Afterwards, cells were incubated with primary antibody for 1 hour at room 
temperature (RT), washed and incubated with secondary antibody conjugated to a fluorochrome 
for 1 hour at RT. All antibodies were diluted in blocking solution. The dilution was specific for each 
antibody used (see Table 2). Finally, the coverslips were washed and the cells nuclei were 
counterstained with diamidino-2-phenylindole (DAPI). All washing steps consisted of 3 washes 
with PBS for 10 minutes; all incubations were performed in a humidified chamber. 
Immunofluorescence in tissue sections was performed as described above, with the 
exception that primary antibodies were incubated overnight at 4°C, and blocking solution was: 5% 
BSA + 5% FBS + 0,1% Triton x-100. 
Table 2 – List of antibodies used in immunofluorescence experiments.   
Antibody Reference 
Rabbit anti-IBA1 
(1:500 ICC and IHC) 
016-20001 (Wako) 
Rabbit anti-iNOS 
(1:200 ICC) 
Sc-650 (Santa Cruz Biotechnology) 
Rabbit anti-Profilin 1 
(1:50 ICC and IHC) 
ab50667 (Abcam) 
 
2.11. Image acquisition and fluorescence intensity 
quantification  
Image acquisition was performed using a Leica DMI6000B inverted microscope coupled 
with a digital CMOS camera (ORCA-Flash4.0 V2, Hamamatsu Photonics). A PlanApo 63X 1.3NA 
glycerol immersion objective was used. Images obtained in 4X4 binning were exported as TIF 
using Leica LAS AF. Fluorescence intensity was quantified in Fiji software. Firstly, the background 
was subtracted using 50%-off pixels radius using rollerball algorithm. Cells were then segmented 
using different algorithms with standard thresholds according to the fluorescence pattern 
obtained: Otsu algorithm was used for Pfn1 and CellRox staining, while Huang algorithm was used 
for iNOS and IBA-1 staining. Individual segmented cells were transposed to ROI manager in FIJI. 
Only particles larger than 50 pixels were considered. Finally, a mean grey value for the intensity of 
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each cell was retrieved using the multi measure function and the mean fluorescence intensity for 
each group was obtained. 
2.12. Gene expression analysis  
2.12.1. RNA isolation  
The mRNA was isolated using Direct-zol™ RNA MiniPrep according to the manufacturer’s 
instructions. Briefly, adherent cells (approximately 2×106 cells per 100 mm2 dish) were lysed 
directly in culture dish with 1mL of TRI reagent. The TRI reagent was mixed by pipetting and it was 
added 1 mL of absolute ethanol. The samples were loaded into spin columns where the RNA was 
purified with several washing steps after being bound to the column. The RNA was eluted in 30µL 
DNase/RNase free water. RNA concentration was measured by NanoDrop at 260nm OD and the 
purity was determined using OD260/OD280 ratio. All samples used had OD260/OD280 ratios between 
1.8 and 2.1. The samples were stored at -80°C until use. 
2.12.2. cDNA synthesis   
Reverse transcription was performed using SuperScript™ III First-Strand Synthesis 
SuperMix for qRT-PCR according to manufacturer’s instructions. Briefly, cDNA was synthetized 
from 500ng of total RNA. For each reaction 10µL of 2×RT Reaction MIX, 2µL of RT Enzyme Mix, 
500µg of RNA and DEPC-treated water were mixed in a final volume of 20µL. The reaction was 
prepared on ice and incubated for 10 minutes at 25°C. Afterwards, the samples were incubated at 
50°C for 30 minutes and the reaction was terminated at 85°C for 5 minutes. The remaining RNA 
was digested by adding 1μL of 2U E. Coli RNase H to each reaction and incubating for 20 minutes 
at 37°C. The samples were stored at -20°C until use.  
2.12.3. Quantitative RT-PCR  
qRT-PCR was performed using iQTM5 multicolour real time PCR system (Bio Rad). The 
reaction was prepared with iQ™ SYBR® Green Supermix according to the manufacturer protocol. 
Briefly, a master mix was prepared containing 10µl of iQ™ SYBR® Green Supermix, reverse and 
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forward primers (primers sequences and concentrations are listed in table 3) and nuclease-free 
water to reach a final volume of 20µl per reaction. The mix was distributed into a 96-well qPCR 
plate. Each sample was run in duplicate. The general cycling protocol was: initial denaturation at 
94°C for 3 minutes, followed by 40 cycles of denaturation, annealing and extension (see optimized 
details in appendix I). Subsequently to the PCR reaction, the temperature was raised from 55°C to 
95°C to generate a melting curve. 
Table 3 - List of primers used in PCR with respective sequences and concentrations used. 
 
Results were analysed using iQTM5 Optical System software version 2.1 (Bio Rad). No 
temple controls (NTC) were always performed to exclude contamination during preparation of 
PCR. Melting point analyses were performed to ensure single amplified products. Gene expression 
was extrapolated based on standard curves generated with cDNA dilution series for each gene. 
Gene expression was normalized for the housekeeping gene Ywhaz (tyrosine 3-
                                                          
*
 kindly supplied by Dr. Tiago Duarte (Institute for Molecular and Cell Biology - IBMC, Oporto, Portugal) 
Primers Sequences (5’– 3’) 
Forward Reverse [ ]  
IL-10 ATCCGGGGTGACAATAACTG TGTCCAGCTGGTCCTTCTTT 200nM  
IL-1β TAAGCCAACAAGTGGTATTC AGGTATAGATTCTTCCCCTTG 250nM  
IL-6 ACTCATCTTGAAAGCACTTG GTCCACAAACTGATATGCTTAG 300nM  
Profilin 1 CGTAGGCTACAAGGACTCGC GGTCTTTGCCTACCAGGACA 200nM  
TNF CTCACACTCAGATCATCTTC GAGAACCTGGGAGTAGATAAG 200nM  
Ywhaz GATGAAGCCATTGCTGAACTTG GTCTCCTTGGGTATCCGATGTC 250nM  
HO-1* GAAGGGTCAGGTGTCCAGAGAAGG CGCTCTATCTCCTCTTCCAGGGC 200nM  
TXNRD1* CAGGGTGACTGCTCAATCCACAAAC CTCTTCCTACCGCCAGCAACACTG 200nM  
GCLC* AGGTTGACGAGAACATGAAAGTGGC CCGCCTTTGCAGATGTCTTTCCTGA 200nM  
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monooxygenase/tryptophan 5-monooxygenase activation protein, zeta (Bonefeld, Elfving et al. 
2008). Relative gene expression analyses were performed using the Livak method (Livak and 
Schmittgen 2001). 
2.12.4. End-point PCR 
End-point PCR was performed with GoTaq® Green Master Mix. To each reaction, cDNA, 
6,25 µl of master mix, 1 µl of forward and reverse primer at 5µM, and 3,25 µl of nuclease free 
water were added. The reaction consisted in 3 minutes of initial denaturation, followed by 30 
cycles of 20 seconds denaturation at 95°C, 30 seconds annealing at 59°C and 30 seconds 
extension at 72°C. The reaction ends with additional 10 minutes of elongation at 72°C and the 
samples were cooled at 4°C. PCR was run on control gene Ywhaz. PCR products were run at 100V 
in 1% (w/v) agarose gel in Tris/acetate/EDTA buffer, containing ethidium bromide. Images were 
captured in Gel Doc XR+ system (Bio Rad). 
2.13. Protein expression analysis  
2.13.1. Total protein extracts  
After washing twice with PBS, cells were homogenized in RIPA-DTT lysis buffer (50mM Tris 
base, pH 8.0; 150mM NaCl; 1% NP-40; 0,5% Sodium deoxylcholate; 0,1% SDS; 1mM EDTA; 100mM 
DTT) supplemented with protease (1:100) and phosphatase (1:100) inhibitor cocktail. Adherent 
cells were scraped off from the dish with a plastic cell scraper, transferred to a 1,5mL tube and 
sonicated. 
2.13.2. Nuclear and cytosolic extracts  
Nuclear and cytosolic extracts were prepared using NucBusterTM Protein Extraction Kit 
according to the manufacturer’s instructions. Briefly, adherent cells were trypsinized to obtain a 
single cell suspension. Cells were centrifuged (200g for 10 minutes), the supernatant was 
discarded and the pellet was resuspended in NucBuster Extraction Reagent 1. The mix was 
homogenized and incubated on ice for 5 minutes. Afterwards, the mix was vortexed and 
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centrifuged at 16000g for 5 minutes at 4°C. The supernatant corresponding to the cytosolic 
fraction was collected and immediately stored at -80°C. The pellet was washed in PBS and 
resuspended in NucBuster Extraction Reagent 2 with protease inhibitor (1:50) and 100mM DTT. 
The mix was vortexed, incubated on ice for 5 minutes, vortexed again and the nuclear fraction 
was collected and immediately stored at -80°C until use. 
2.13.3. Protein quantification  
The protein content was quantified by the bicinchoninic acid (BCA) method (Pierce™ BCA 
Protein Assay Kit), which is based on the reduction of Cu2+ to Cu1+ by protein in an alkaline 
medium with colorimetric detection of the Cu1+ by BCA. The protein amount was determined by 
comparing total protein concentration with a protein standard (BSA). A standard solution of 2 
mg/mL BSA was diluted to concentrations ranging between 12.5 to 800 µg/µL and applied in 
duplicates to 96 multiwell plate in other to construct a standard curve. The samples were diluted 
(1:9) and were applied in duplicates to the same plate. The BCA reagent was added and the 
samples were incubated at 37°C for 30 minutes. The optical density was recorded at 562 nm in 
the Synergy 2 plate reader (BioTeK). Protein concentration was calculated using the following 
equation:   
protein concentration (µg/µL) =
(samples absorbance mean−blank absorbance)× standard curve slope
sample dilution after denaturation  
  
 
2.13.4. Western blot  
For sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-Page), proteins 
were diluted (5/6) in 6X denaturation buffer (0.5M Tris-HCl/0,4% SDS, pH 6.8; 30% glycerol; 10% 
SDS; 0.6M DTT; 0,01% bromophenol blue) and denatured by heating at 95°C for 10 minutes. After 
denaturation, samples were loaded in 15% acrylamide/bisacrilamide gels and were separated by 
SDS-PAGE using protein running buffer (250 mM Tris, 1.92 M glycine, 1% SDS). Proteins were then 
electrophoretically transferred (1.3A, 2.5V, 15 minutes) to a polyvinylidene difluoride (PVDF) 
membrane (Immobilon-P, Millipore) using the Trans-Blot® Turbo™ Transfer System (Bio Rad). The 
membranes were then blocked in 5% low-fat milk in TBS-T buffer (20mM Tris; 0.137M NaCl; 0.1% 
Tween 20) for 1 hour at room temperature. The primary antibodies were incubated overnight at 
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4°C in 3% BSA (table 4). After washing tree times (3 X 10 minutes) with TBS-T, membranes were 
incubated with secondary antibody conjugated with horseradish peroxidase (HRP) for 1-2 hours at 
room temperature. For the loading control, membranes were incubated with the primary 
antibodies mouse anti-Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) (total extracts) and 
rabbit anti-Histone 3 (H3) (nuclear extracts). Protein immunoreactive bands were developed using 
an enhanced chemiluminescence kit (Life Technologies). Images were acquired in ChemiDoc XRS 
System (BioRad) and quantified using the Image LabTM Software version 4.1. 
Table 4 - List of antibodies used in western blotting.  
Antibody Reference 
Rabbit anti-IBA1 (1:100) 016-20001 (Wako) 
Rabbit anti-iNOS (1:200) Sc-650 (Santa Cruz Biotechnology) 
Rabbit anti-Profilin 1 (1:1000) ab50667 (Abcam) 
Mouse anti-GAPDH (1:5000) MAb 6C5 (HY tests) 
Rabbit anti-H3 (1:5000) ab1791 (Abcam) 
Rabbit anti-NF-κB (1:200) sc-372 (Santa Cruz Biotechnology) 
Phosphoprofilin-1 (1:1000) pS137-PFN1 (Shao and Diamond 2012) 
 
2.14. FRET 
2.14.1. Cell preparation 
Primary cortical microglial cells were plated on plastic-bottom culture dishes (μ-Dish 35 
mm2, iBidi), approximately 1×105 cells per mL. Cultures were infected (300µL virus: 1200 µL 
medium) 24 hours after plating (as described above) and transfected with plasmids encoding FRET 
probes 48 hours before image acquisition. Transfection was performed with jetPRIME® reagent 
with similar protocol previously described for HEK293T cells. For each plate, 20µL jetPRIME® 
buffer, 3 µg of plasmid and 2 µL of jetPRIME® were used. Plasmids used: pFRET HSP33 cys (Guzy, 
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Hoyos et al. 2005), pDisplay FLIPE-600n (Okumoto, Looger et al. 2005) and Raichu-Rac1 probe 
(Itoh, Kurokawa et al. 2002). Transfection medium was replaced by fresh medium 4 hours after 
transfection.  
Stable cell lines used in FRET experiments were plated at the same density as primary 
cells and were transfected with plasmids for FRET probes 24 hours after plating. Transfection 
conditions used were similar to those described above, except that 1µg of plasmids was used and 
cell imaging was performed 24 hours after transfection. Prior to image acquisition, cell medium 
was replaced with 2 mL of HBSS. 
2.14.2. Image acquisition and FRET quantification 
Image acquisition was performed with a Leica DMI6000B inverted microscope equipped 
with a high-speed low vibration external excitation/emission filter wheels (Fast Filter Wheels, 
Leica Microsystems), a digital CMOS camera (ORCA-Flash4.0 V2, Hamamatsu Photonics) and a 
chamber that allows regulation of temperature and O2 levels. Individual cells were monitored 
over time and at each time point CFP (CFP excitation and CFP emission) and FRET (CFP excitation 
and YFP emission) images were captured, using different filter combinations.  
Images acquired were exported to Fiji software where they were filtered using a Kalman 
stack macro. The background was subtracted and, if necessary, photo bleaching was corrected 
using an exponential fitting function. Then ratiometric images were generated: CFP/FRET for ROS 
probe and glutamate release probe; FRET/CFP for RAC-1 activation probe. Mean grey intensity 
values were calculated in Fiji software exported to GraphPad Prism software for statistical 
analyses.  
2.15. Statistical analyses 
All data shown in this work represent, at least, 3 independent experiments. The results 
were analysed using Microsoft Excel and GraphPad Prism 6 and statistical analysis was performed 
with GraphPad Prism. Data were presented as mean and standard error of the mean (SEM), 
unless otherwise indicated. Student’s t-test was used in cases where the variances of only two 
groups were compared. One-sample t-test was used when results of a test group were normalized 
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against those of a control group. Paired t-test was used to compare the means of two related 
groups. A one-way analysis of variance (ANOVA) was used to compare 3 or more data sets. 
Results were considered statistically significant when p value was smaller than 0.05. 
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3. Results  
3.1. Dissecting the role of Pfn1 in microglial cell 
function 
Pfn1 is an actin binding protein ubiquitously expressed, except in muscle cells (Carlsson, 
Nystrom et al. 1977, Witke 2004, Jockusch, Murk et al. 2007). Differences in Pfn1 expression play 
significant roles in both the dynamics of actin cytoskeleton and signal transduction cascades of 
several biological processes (Jockusch, Murk et al. 2007, Birbach 2008). Previously, Dong and 
colleagues (2004) observed the expression of Pfn1 mRNA in microglial cells from the hippocampus 
by in situ hybridization (Dong, Ying et al. 2004). In order to better characterize the expression of 
Pfn1 in microglial cells we performed an RT-PCR to detect the mRNA for Pfn1 in primary purified 
microglial cell cultures and in N9 microglial cell line. The brain cortex and the spinal cord were 
used as positive controls (Murk, Wittenmayer et al. 2012) (fig. 11A). Besides, western blotting was 
used to observe the protein expression of Pfn1 in cultured microglia. The cortex was, again, used 
as positive control (fig. 11B). In order to show microglial Pfn1 expression in vivo, we used sections 
from the brain cortex of the CX3CR1-EYFP mouse (with an EYFP knocked in the Cx3cr1 allele and 
displays fluorescent microglia in the brain). We used imunostaining for Iba-1 as a microglial cell 
marker to confirm the specificity of EYFP fluorescence and we observed that Iba-1 and EYFP 
fluorescence were coincident, indicating that EYFP fluorescence was specific for microglia 
(fig.11C). Then, we performed an immunohistochemistry for Pfn1 and a co-localization analysis. 
We observed that Pfn1 fluorescence was co-localize with EYFP fluorescence (co-localization is 
represented in white), demonstrating microglial Pfn1 expression in vivo (fig. 11D). 
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Figure 11 - Pfn1 expression in microglial cells. (A) The mRNA detection of Pfn1 was assessed by RT-PCR. Cortex and 
spinal cord were used as positive control. ywhaz was used as reference gene. (B) Pfn1 protein detection was 
assessed by western blot in BV-2 microglial cell line. Cortex was used as positive control. GAPDH was used as 
loading control. (C, D) Representative images of CX3CR1-CreERT2 mouse cortex. Imunolabelling for Iba 1 (red) co-
localizes with YFP microglia (green), demonstrating YFP specific signal (C). Immunohistochemistry for Pfn1 (Red) 
shows that this actin-binding protein is expressed in microglial cells (D). Co-localization signal is represented in 
white. Nuclei were stained with DAPI. Images were acquired in confocal microscope. Scale bar: 15 µm (C) 25 µm (D). 
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3.1.1. Pfn1 is less phosphorylated in activated microglia  
Considering that Pfn1 might have a role in microglia activation, we analysed Pfn1 
expression and phosphorylation changes upon a pro-inflammatory stimulation of microglial cells. 
For that, we challenged BV-2 microglial cells with anoxia (95% N2 + 5% CO2 during 4 hours), a 
strategy to activate microglia (Park, Lee et al. 2002, Yao, Kan et al. 2013). Comparing Pfn1 
expression levels between normoxia and anoxia, by western blot, we did not observe significant 
differences in Pfn1 expression, as depicted in fig. 12A and B. We also analysed Pfn1 
phosphorylation at Serine 137 (hereafter termed p-Pfn1). As previously reported, an increase in 
Serine 137 phosphorylation indicates reduced capacity of Pfn1 to modulate actin polymerization 
(Shao, Welch et al. 2008). We observed a significant decrease in Pfn1 phosphorylation induced by 
anoxia (fig. 12A,C), indicating an increased capacity of Pfn1 for polymerizing the actin 
cytoskeleton in activated microglia. Altogether, these data suggested that Pfn1 might have a role 
in microglia activation. 
3.1.2. The effect of Pfn1 knockdown in microglial function 
As we previously demonstrated, the actin polymerization capacity of Pfn1 was increased in 
anoxia-challenged microglia. In order to investigate the role of this protein in microglia activation, 
we performed Pfn1 knockdown in primary cortical microglial cell cultures and in BV-2 microglial 
cell line via lentivirus-mediated shRNA delivery. We confirmed Pfn1 knockdown in primary 
Figure 12 - Pfn1 was less phosphorylated in activated microglia. (A) Western blot and quantification of (B) Pfn1 and (C) 
p-Pfn1 protein relative expression in BV-2 microglia in normoxic and anoxic conditions. GAPDH expression was used as 
loading control. All data are expressed as mean ± SEM normalized to control. N=3, p < 0.05 using one sample t test. 
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Figure 13 - Infection with lentivirus carrying Pfn1 shRNA lead to Pfn1 knockdown. Microglial cells were infected with 
lentivirus carrying Pfn1 shRNA or an empty plasmid (pLKO) as control. Pfn1 levels were quantified 72 hours post-
infection. (A) Relative mRNA levels determined by qRT-PCR in primary microglial cells using ywhaz as a reference gene 
(B) Representative images of Pfn1 (red) immunocytochemistry and fluorescence intensity quantification in primary 
microglial cells. Scale bar: 50µm. (C) Western blot and quantification of Pfn1 protein relative expression in BV-2 
microglia puromycin selected clones. GAPDH expression was used as loading control. All data are expressed as mean ± 
SEM and normalized to control. N=4 (A), N=3(B,C),  p < 0.05 using one sample t test (A,C); paired t test (B). 
microglia, by qRT-PCR (fig. 13A) and immunofluorescence (fig. 13B). Pfn1 knockdown in BV-2 sub-
clones stably expressing Pfn1 shRNAs was confirmed by western blotting (fig. 13C) relative to cell 
carrying an empty control plasmid (pLKO). 
After confirming the efficiency of Pfn1 knockdown, we used this approach to analyse the 
activation status of microglia based on classical activation markers, such as: phagocytosis; 
glutamate release; ROS production; NF-κB activation; iNOS, Iba-1; arginase-1 expression and 
differences in mRNA levels of both pro- and anti-inflammatory cytokines. 
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3.1.2.1. Pfn1 knockdown decreases the phagocytic efficiency of microglia 
We evaluated the phagocytic efficiency of primary cortical microglia. After Pfn1 
knockdown, cells were incubated with inert fluorescent beads for 45 min, fixed and observed in a 
fluorescence microscope. As represented in fig. 14A, Pfn1 knockdown decreased the phagocytic 
efficiency of microglia. We also analysed the expression of Iba-1, a calcium binding protein whose 
expression is associated to membrane ruffling and phagocytosis in microglia (Ohsawa, Imai et al. 
2000) - Iba-1 participates in Rac1 signalling, that is important to coordinate actin remodelling in 
phagocytic process (Imai and Kohsaka 2002). We observed that shPfn1 sable BV-2 cell sub-clones 
express less Iba-1 in comparison to control (fig.14B). Here we concluded that Pfn1 knockdown 
decreased phagocytic efficiency of microglial cells.   
Figure 14 - Pfn1 knockdown decreased the phagocytic efficiency of microglia. (A) Representative images of 
phagocytosis efficiency assay in primary microglial cells. After 71 hours of lentivirus mediated delivery of pLKO and Pfn1 
shRNA, microglial cells were incubated with fluorescence latex beads (green) for 45 minutes and stained with Iba-1 
(red). Scale bar: 50 µm. The graph represents the quantification of phagocytic efficiency. (B) Western blotting and 
quantification of Iba-1 protein relative expression in total extracts of BV-2 microglia puromycin selected clones. GAPDH 
expression was used as loading control. All data are expressed as mean ± SEM and normalized to control. N=4 (A), N=3 
(B), p < 0.05 using unpaired t test (A) and one sample t test (B). 
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3.1.2.2. Pfn1 knockdown regulates microglia anti-inflammatory signature  
In order to investigate anti-inflammatory markers in microglial cell cultures, we first 
analysed NRF2 target genes. This transcription factor regulates the expression of cytoprotective 
genes carrying ARE sequences within their promoters (Rojo, Innamorato et al. 2010, Bryan, 
Olayanju et al. 2013). As previously observed, NRF2 modulates anti-inflammatory activation 
signatures of microglia (Cuadrado, Martin-Moldes et al. 2014, Rojo, McBean et al. 2014). We 
studied NRF2 activation by analysing the mRNA levels of tree NRF2 target genes: glutamate-
cysteine ligase catalytic subunit (Gclc), thioredoxin reductase 1 (Txnrd1) and heme oxygenase-1 
(HO-1) (fig. 15A). We could not observe any differences in Gclc or Txnrd1 mRNA levels, although 
we found a significant decrease in the mRNA for HO-1 in Pfn1 knocked down microglia, suggesting 
a reduced transcriptional activity of NRF2. We also analysed the expression of IL-10 and arginase 1 
as other anti-inflammatory markers. We did not detect any difference between IL-10 mRNA levels 
of control and Pfn1 knocked down cells (fig. 15B). On the other hand, arginase 1 expression was 
significantly decreased in Pfn1 knocked down microglia when compared to the control (fig. 15C). 
These results indicated that Pfn1 knockdown decreases the levels of anti-inflammatory mediators 
in microglial cells. 
3.1.2.3. Pfn1 knockdown reduces the pro-inflammatory activation 
markers in microglia  
NF-κB activation is a key step for microglia activation (Oeckinghaus and Ghosh 2009). 
Translocation of NF-κB to the nucleus induces the expression of several pro-inflammatory signals, 
for instance, iNOS and pro-inflammatory cytokines (Rojo, McBean et al. 2014). We observed that 
Pfn1 knockdown decreased NF-κB in the nucleus of BV-2 microglial cells in comparison to control 
microglia (fig. 16A). We also analysed mRNA levels of pro-inflammatory cytokines in primary 
microglia and observed a significant reduction in IL-6 and IL-1β relative expression in Pfn1 
knockdown cells (fig. 16B). Regarding TNF, there was no significant difference between control 
and Pfn1 knocked down cells. Moreover, we evaluated the expression of iNOS in primary 
microglia (fig. 16C) and BV-2 microglia (fig. 16D) by immunofluorescence and western blotting, 
respectively. In both cases, knocking down Pfn1 led to a significant decrease in iNOS expression. 
These results suggested that Pfn1 knockdown decreases the pro-inflammatory activation of 
microglia. 
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Figure 15 - Pfn1 knockdown regulated microglia anti-inflammatory signature. (A) Relative mRNA levels of NRF2 
target genes (Glutamate-cysteine ligase catalytic subunit -Gclc; thioredoxin reductase 1-Txnrd1; heme oxygenase-1 
-HO-1) determined by qRT-PCR in control (plKO) and Pfn1 knockdown (Pfn1 shRNA) primary microglial cells. (B) 
Relative mRNA levels of anti-inflammatory cytokine IL-10 in control (plKO) and Pfn1 knockdown (Pfn1 shRNA) 
primary microglial cells. Ywhaz was used as reference gene. (C) Western blotting for Arginase 1 and quantification 
of its relative expression in total extracts of BV-2 microglia puromycin selected clones. GAPDH expression was used 
as loading control. All data are expressed as mean ± SEM and as percentage of control. N=3, p < 0.05 using one 
sample t test. 
       
44 
 
 
Figure 16 - Pfn1 knockdown reduced the pro-inflammatory activation markers in microglia. (A) Western blot for NF-κB 
and quantification of its relative expression in nuclear extracts of BV-2 microglia (puromycin selected clones for pLKO 
and Pfn1 shRNA). Histone 3 (H3) expression was used as nuclear loading control. (B) Relative mRNA levels of pro-
inflammatory cytokines (TNF, IL-6 and IL-1β) were determined by qRT-PCR in control (plKO) and Pfn1 knockdown (Pfn1 
shRNA) primary microglial cells. ywhaz was used as reference gene. (C) Representative images of iNOS (red) 
immunocytochemistry and fluorescence intensity quantification in primary microglial cells. Nuclei were stained with 
DAPI (blue). Scale bar: 50 µm. (D) Western blot for iNOS and quantification of its relative expression in total extracts of 
BV-2 microglia puromycin selected clones. GAPDH was used as loading control. All data are expressed as mean ± SEM 
and as normalized to control. N=3, p < 0.05 (A-C), p < 0.01 (B) and p < 0.0001 using one sample t test. 
NF-κB 
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3.1.2.4. Pfn1 knockdown has no effect on glutamate release  
Increased glutamate release is also an activation parameter for microglia activation (Piani, 
Spranger et al. 1992, Barger and Basile 2001). In order to test whether Pfn1 reduction impacts on 
glutamate release we used FRET-based live cell imaging with a high sensitive biosensor for 
detecting glutamate release (FLIPE 600nSurface). The functioning of this biosensor is represented in 
fig. 17A.  
Figure 17 - Pfn1 knockdown had no effect on glutamate release. After Pfn1 knockdown, primary microglial cells were 
transfected with the glutamate release FRET probe (FLIPE probe). Imaging was performed 42 hours post-transfection. 
(A) Schematic illustration of glutamate release FRET probe (Socodato, et al. 2014). (B) Representative images of FLIPE 
probe in control and Pfn1 knockdown in primary cortical microglia. CFP/FRET images were colour-coded using the colour 
ramp showed. Scale bar: 10 µm. Graph demonstrating CFP/FRET amplitudes from 6 cells in pLKO and 9 cells in Pfn1 
shRNA during 8 minutes imaging. Data are expressed as mean ± SEM, no significant changes were found using unpaired t 
test. 
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FLIPE 600nSurface was composed of two fluorescent molecules: enhanced cyan fluorescent 
protein (eCFP) and the YFP variant Venus. These fluorescent molecules were linked by a 
glutamate/aspartate binding protein (ybeJ). Without glutamate, these fluorescent molecules were 
close enough to FRET. When glutamate bound to aspartate binding protein, there are 
conformational changes that separate the fluorescent molecules, reducing FRET. Once FLIPE 
600nSurface was tagged to the cell surface, it allowed detecting the release of glutamate specifically, 
without interference of glutamate metabolism (Itoh, Kurokawa et al. 2002). As represented in fig. 
17B, there were no significant changes in the amplitude of CFP/FRET ratio between control and 
microglia knocked down for Pfn1, suggesting that Pfn1 did not affect glutamate release in 
microglia. 
3.1.2.5. Pfn1 knockdown decreases ROS production 
Increased ROS production and release by microglia is a hallmark of activation (reviewed in 
(Rojo, McBean et al. 2014). To study ROS accumulation in microglia, we used the CellROX® deep 
red reagent, a fluorogenic ROS probe. We observed that Pfn1 knockdown resulted in robust 
decrease (up to 80%) of CellROX® fluorescence (fig. 18A), indicating a dramatic reduction in ROS 
production, compared to control microglia. To corroborate this intense reduction in ROS 
production, we, again, used a FRET-based live cell imaging, with a high sensitive ROS biosensor, 
the HSP FRET probe. This FRET probe was composed by two fluorescent proteins (eCFP and eYFP) 
linked by a ROS sensitive domain (Hsp33; fig. 18B). Without ROS generation, these fluorescent 
molecules were close enough to produce FRET. When Hsp33 protein was oxidized by ROS, the 
oxidation promoted conformational changes in the probe, resulting in the separation of the 
fluorescent molecules, reducing FRET (Guzy, Hoyos et al. 2005). We observed that the amplitude 
of CFP/FRET ratio was decreased in Pfn1 knocked down microglia when compared to control cells, 
indicating less ROS generation (fig. 18C). Here we concluded that Pfn1 was crucial to the ROS 
production in microglial cells. 
In line with this, we asked if Pfn1 would also be important for ROS production upon 
microglia activation. For that we challenged primary microglial cells with hypoxia, a well-known 
pro-inflammatory stimulus that increases ROS production in microglia (Wong and Crack 2008). We 
clearly observed an increased in ROS production in control cells submitted to hypoxia (2% O2). 
However, microglial cells knocked down for Pfn1 did not increase the ROS production in response 
to hypoxia (fig. 19). We concluded that Pfn1 was not only important for basal ROS production, but 
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also for hypoxia-induced ROS generation. This finding supported the importance of Pfn1 for the 
generation of ROS in microglia. 
 
  
Figure 18 - Pfn1 knockdown lead to dramatic decrease in ROS production in microglial cells. (A) Representative images 
of CellROX® fluorescence (green) in microglial control cells (pLKO) and in cells with decreased Pfn1 expression (Pfn1 
shRNA). Nuclei were stained with DAPI (blue). 71 hours post-infection with lentivirus, cells were incubated with 
CellROX® probe for 30 minutes. Scale bar: 50 µm. The graph shows CellROX® fluorescence intensity quantification. (B) 
Schematic illustration of the ROS FRET probe (HSP) (Socodato, et al. 2014). (C) Representative images of HSP ROS probe 
in control and Pfn1 knockdown in primary cortical microglia. After Pfn1 knockdown, primary microglial cells were 
transfected with a HSP ROS FRET probe. Imaging was performed 42 hours post-transfection. CFP/FRET images were 
colour-coded using the colour ramp showed. Scale bar: 10 µm. Graph demonstrating CFP/FRET amplitudes from 9 cells 
in pLKO and 9 cells in Pfn1 shRNA during 8 minutes imaging. Data are expressed as mean ± SEM and normalized to 
control (A). p < 0.01 (A) and p < 0.05 (B) using paired t test and unpaired t test, respectively. 
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3.2. Dissecting the molecular mechanism for Pfn1-
regulated ROS production in microglia  
Given that the knockdown Pfn1 had a dramatic effect in ROS production and the 
importance of redox signalling for the modulation of microglia responses, we decided to better 
investigate the mechanism by which Pfn1 affects ROS generation. 
3.2.1. Does Pfn1 affect ROS generation in a NOX dependent manner? 
Considering that NOX is the main source of ROS generation in microglia, it would be 
plausible that Pfn1 might affect ROS generation in a NOX-dependent manner. To test this 
hypothesis we compared the status of Rac1 activation (which is important for NOX complex 
assemble) in Pfn1 knockdown and control microglia. For that we used the Raichu-Rac1 FRET probe 
to detect differences in Rac1 activation. This probe was composed of a Rac1 interactive binding 
motif of PAK and two fluorescence proteins: YFP and CFP (fig. 20A). Inactive Rac1 (GDP-Rac1) did 
Figure 19 - Pfn1 knockdown prevented ROS increase upon hypoxia. After Pfn1 knockdown, primary microglial cells 
were transfected with the HSP ROS FRET probe. Imaging was performed 42 hours post-transfection. Each cell was 
studied for 10 minutes in normoxia conditions, followed by 30 minutes in hypoxia (2% O2). At the left, graph showing 
normalized CFP/FRET ratio in time-lapse. CFP/FRET emission ratios were normalized at last frame before hypoxia. In the 
middle, CFP/FRET representative images of HSP ROS probe in control and Pfn1 knockdown in primary cortical microglia 
both in normoxia conditions and at 25 minutes of hypoxia stimulation. Scale bar: 10 µm. CFP/FRET images were colour-
coded using the colour ramp showed. At the right, graph demonstrating CFP/FRET mean from 5 cells in pLKO and 4 cells 
in Pfn1 shRNA at 25 minutes of hypoxia. Data are expressed as mean ± SEM. p < 0.05 using unpaired t test. 
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not bind to PAK, so fluorescent molecules were distant and do not produce FRET. On the other 
hand, activated Rac1 (GTP-Rac1) bound to PAK, producing FRET upon CFP excitation. In our 
experiment we observed that the amplitude of FRET/CFP ration of Raichu-Rac1 was decreased in 
Pfn1 knockdown microglia, indicating that Rac1 was less activated in this context (fig. 20B). This 
result was consistent with our hypothesis that Pfn1 might influence ROS generation in a NOX-
dependent manner. 
We also analysed Rac1 activity upon hypoxic challenge (fig. 20C). Considering our 
hypothesis, we were expecting that Rac1 activation would follow the levels of ROS production in 
hypoxia. In fact, there was a decrease in Raichu-Rac1 activation in Pfn1 knockdown hypoxia. 
However, we didn’t observe an increase in Rac1 activation upon hypoxia in control microglia. All 
together, these results suggested that the hypoxia-mediated ROS generation was independent of 
NOX. 
3.2.2. How different Pfn1 mutants affect ROS generation? 
In order to better understand the importance of Pfn1 in ROS production in microglia, we 
studied how the disruption of different ligand sites in Pfn1 would impact ROS production in 
microglia. We transfected CHME3 human microglial cell line with different Pfn1 plasmids: Pfn1 
WT - Pfn1 wild-type; Pfn1R74E - actin binding domain defective; Pfn1H133S- PLP binding domain 
defective  and Pfn1 S137D - phospho-mimetic. Firstly, we confirmed the overexpression of Pfn1 
constructs in microglia by western blotting (fig. 21A) and then, we compared, by FRET, the levels 
of ROS production among the different Pfn1 constructs. We observed a significant decrease in 
ROS production in microglia overexpressing Pfn1 with mutations in the actin (Pfn1R74E) and PLP 
(Pfn1H133S) binding domains (fig. 21B) in comparison to microglia overexpressing the Pfn1 WT. 
Regarding the phospho-mimetic Pfn1 (Pfn1 S137D) construct, there was no significant differences in 
basal ROS production when compared to the control (Pfn1 WT).  
We also analysed the effect of Pfn1 mutants in ROS generation during hypoxia. We 
observed a significant decrease in ROS generation in microglia overexpressing all the Pfn1 
mutants relative to Pfn1 WT (fig. 21C). However, the phospho-mimetic Pfn1 construct was much 
less effective in preventing the increase in ROS production during hypoxia. These results showed 
that defects, in the actin and in the PLP binding domain might directly impact the Pfn1-mediated 
ROS production in microglia. 
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Figure 20 - How Pfn1 knockdown affected Rac1 activity in microglial cells. (A) Schematic illustration of Raichu-Rac1 
FRET (Matsuda et al., 2002). (B) Representative images of Raichu-Rac1 FRET probe in control and Pfn1 knockdown in 
primary cortical microglia. After Pfn1 knockdown, primary microglial cells were transfected with plasmid for FRET probe. 
Imaging was performed 42 hours post-transfection. FRET/CFP images were colour-coded using the colour ramp showed. 
Scale bar: 10 µm. Graph demonstrating FRET amplitudes from 11 cells in pLKO and 11 cells in Pfn1 shRNA during 10 
minutes imaging. (C) FRET/CFP representative images of Raichu-Rac1 FRET in control and Pfn1 knockdown BV-2 
microglia both in normoxia conditions and at 20 minutes of hypoxia. Images were colour-coded using the colour ramp 
showed. Scale bar: 10 µm. Each cell was studied for 10 minutes in normoxia conditions, followed by 45 minutes in 
hypoxia (2% O2). The graph shows normalized FRET/CFP ratio in time-lapse. CFP/FRET emission ratios were normalized 
at last frame before hypoxia. Data are expressed as mean ± SEM. N=3-4, p < 0.05 using unpaired t test. 
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Figure 21 - How different Pfn1 mutants affected ROS generation. (A) Western blot and graphic representation of total 
Pfn1 protein relative expression in BV-2 microglia 24 hours post-transfection with Pfn1 wild type (Pfn1 WT) and 
different mutants for Pfn1: Pfn1
R74E 
- actin binding domain defective Pfn1; Pfn1
H133S
- PLP binding domain defective Pfn1; 
Pfn1
 S137D
 – phospho-mimetic Pfn1. Non transfected BV-2 microglia was used as control. GAPDH expression was used as 
loading control. (B) CFP/FRET representative images of HSP ROS probe in BV-2 microglia transfected with Pfn1 WT and 
Pfn1 mutants both in normoxia conditions and at 15 minutes of hypoxia. Scale bar: 10 µm. CFP/FRET images were 
colour-coded using the colour ramp showed. (C) Graph demonstrating CFP/FRET amplitudes in Pfn1 wild type (Pfn1 WT) 
and different mutants during 5 minutes imaging in normoxic conditions. (D) Graph demonstrating normalized CFP/FRET 
ratio in time-lapse during normoxia and hypoxia. CFP/FRET emission ratios were normalized at last frame before 
hypoxia. Imaging was performed during 30 minutes in hypoxia. All data are expressed as mean ± SEM and normalized to 
control (A,C). p < 0.05 using one-way ANOVA. 
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4. Discussion 
Chronic activation of microglia induces neuronal cell death and is implicated in many 
neurodegenerative diseases, especially though the production and release of ROS, NO and 
glutamate (Ransohoff and Perry 2009, Kettenmann, Hanisch et al. 2011, Rojo, McBean et al. 
2014). Understanding the mechanisms underlying microglial cell activation is important to define 
targets and develop strategies to counteract the noxious effects of microglia activation. A work by 
Dong and colleagues (2004) showed that Pfn1, an actin-binding protein, was upregulated in 
activated microglia, which suggested that it may play a role in the process of microglia activation. 
However, this putative role of Pfn1 remains elusive. 
The aim of the present work was to investigate the role of Pfn1 in microglial cell function. 
We demonstrate that (i) Pfn1 is more active in hypoxia-challenged microglia, (ii) Pfn1 modulates 
microglia pro- and anti-inflammatory signatures, and (iii) Pfn1 plays a critical role in ROS 
production by microglia. We also provide insights on the impact of Pfn1 on ROS production in 
microglia. 
Pfn1 expression has been detected in almost every mammalian cell type studied to date, 
including monocyte-derived macrophages (Kadiu, Ricardo-Dukelow et al. 2007) and microglial 
cells (Dong, Ying et al. 2004). Here, we detected Pfn1 mRNA and protein expression in primary 
microglial cell cultures, in microglial cell lines and in microglia from the brain cortex in vivo. As 
expected, we observed that microglial cells express high levels of Pfn1 (fig. 11).  
Considering that (i) Pfn1 plays an essential role in promoting actin dynamics and (ii) the 
microglial cell activation process is associated with morphological changes, migration into 
damaged areas and increased phagocytic ability, which are strictly dependent on rearrangements 
of the actin cytoskeleton, it is conceivable that Pfn1 may play a critical role in microglia activation. 
Moreover, there is evidence relating macrophage activation to an increase in Pfn1 expression. An 
increase in Pfn1 expression has been described in macrophages within the atherosclerotic lesions 
of apoE null mice (Romeo, Frangioni et al. 2004). Macrophages within atherosclerotic lesions are 
activated and drive inflammatory processes (Dickhout, Basseri et al. 2008). 
In order to test the hypothesis that Pfn1 plays a role in microglial activation, we analysed 
Pfn1 expression and phosphorylation in BV-2 microglia upon anoxia, which triggers a pro-
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inflammatory response (fig.12). Several studies support that, both in vivo or in vitro, challenging 
microglial cells with reduced levels of oxygen leads to their activation with concomitant 
production of pro-inflammatory mediators, such as ROS, NO, and TNF, IL-1β and iNOS expression 
(Park, Lee et al. 2002, Wong and Crack 2008, Yao, Kan et al. 2013). In our model, Pfn1 protein 
content did not change upon anoxia. This result was apparently not in agreement with the 
increased Pfn1 mRNA levels reported by Dong and colleagues in activated microglial cells. 
However, these authors reported differences in the mRNA level, which do not necessarily 
translate into differences in protein expression. Also, the authors used a different model in which 
microglial cells were activated in the mouse hippocampus after unilateral destruction of the 
entorhinal cortex, while we used BV-2 microglia activated by hypoxia. Regarding the 
phosphorylation at Ser-137, we observed a decrease after hypoxia. Since Pfn1 phosphorylation at 
Ser-137 inhibits actin polymerization (Sathish, Padma et al. 2004, Shao, Welch et al. 2008), these 
results indicated that Pfn1 was more active upon hypoxia. Altogether, our data suggested a role 
for Pfn1 in microglia activation. 
To dissect the role of Pfn1 in microglial cell function we knocked down Pfn1 expression in 
microglia cultures. We observed decreased phagocytic efficiency in Pfn1 knocked down microglial 
cells (fig. 14A). Taking into consideration the importance of the actin cytoskeleton to the 
phagocytic process and to actin dynamics, these results were expected and agree with our 
hypothesis that Pfn1 is important for microglia activation. Furthermore, the idea that Pfn1 is 
important for phagocytosis is supported in the literature. Coppolino and colleagues showed that 
Pfn1 is recruited to nascent phagosomes (Coppolino, Krause et al. 2001) and also, Pfn1 siRNA 
decreases phagocytosis of serum (C3bi)-opsonized zymosan in macrophages (Kim, Moon et al. 
2012). 
Besides phagocytic efficiency, we also compared Iba-1 expression in Pfn1 knocked down 
and control microglia. Iba-1 expression is upregulated in situations that cause microglia activation, 
including ischemia (Ito, Tanaka et al. 2001) and brain diseases (Mori, Imai et al. 2000). Iba-1 also 
co-operates with both F-actin and signalling molecules to promote membrane ruffling and 
phagocytosis in monocytic cells (Ohsawa, Imai et al. 2000). There is evidence that (i) Iba-1 is 
recruited from the cytosol to phagocytic cups during phagocytosis of zymogen particles induced 
by M-CSF and (ii) Iba-1 mutations inhibit zymogen phagocytosis (Ohsawa, Imai et al. 2000). In our 
context, we observed decreased Iba-1 expression in Pfn1 knocked down cells, which was in 
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accordance with the decreased phagocytic efficiency that we had found, suggesting that microglia 
became less activated upon Pfn1 knockdown (fig.14B). 
Moreover, there is evidence that Iba-1 participates in Rac1 signalling (Ohsawa, Imai et al. 
2000). Rac1 is a member of the Rho family of small GTPases, which are key players in the 
dynamics of the actin cytoskeleton. These proteins regulate signalling pathways that link the 
assembly and organization of the actin cytoskeleton to external and internal signals. In particular, 
the Rho GTPase Rac1 induces lamellipodia formation and plays an important role in regulation of 
other cellular processes, including Fcγ receptor-mediated phagocytosis in macrophages and 
NADPH oxidase-dependent ROS production (Castellano, Montcourrier et al. 2000), Cheng, Diebold 
et al. 2006, McCann and Roulston 2013). In agreement with previous results, we observed that 
Rac1 activity was decreased in Pfn1 knocked down microglia, both in basal and hypoxia-
challenged cells (fig.20). 
Since our results support the hypothesis that Pfn1 is important for microglia activation, we 
studied the impact of Pfn1 knockdown on the levels of anti- and pro-inflammatory mediators. 
Regarding the former, we analysed NRF2 activity, IL-10 mRNA expression, and arginase-1 protein 
expression. NRF2 is a master regulator of the cellular redox state and is implicated in 
inflammation control (Cho, Reddy et al. 2004, Rojo, Innamorato et al. 2010, Bryan, Olayanju et al. 
2013). In microglia, this function was demonstrated in NRF2-deficient mice challenged with 
systemic administration of LPS. Authors observed increased neuroinflammation in NRF2-deficient 
mice comparing to wild type animals (Innamorato, Rojo et al. 2008). Also, NRF2 induction with 
sulforaphane decreased the production of microglial pro-inflammatory mediators (iNOS, IL-6 and 
TNF) in response to LPS (Innamorato, Rojo et al. 2008). To study the impact of Pfn1 knockdown in 
NRF2 activity, we analysed the relative expression of Txnrd1, Gclc, and HO-1 (NRF2 target genes). 
Our results showed that HO-1 was reduced in microglial cells with decreased Pfn1 levels (fig. 15A). 
HO-1 is the inducible isoform of heme-oxygenase that is responsible for catalysing heme 
degradation, generating carbon monoxide, biliverdin and free iron as end products. These 
molecules exert protective effects, for instance, by scavenging free radicals (reviewed in (Rojo, 
McBean et al. 2014). Also, different studies described that HO-1 end products decreases  
monocyte activation, with inhibition of NOX activity and TLR-4 signalling (Lanone, Bloc et al. 2005, 
Taille, El-Benna et al. 2005, Nakahira, Kim et al. 2006). Moreover, it has been reported that anti-
inflammatory compounds used to counteract over-activation of microglial cells are responsible for 
increasing HO-1 expression (Lee, Ko et al. 2014, Gan, Zhang et al. 2015). 
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Concerning arginase 1, we observed a decrease in its protein expression upon Pfn1 
knockdown (fig.15C). As mention in previous sections, arginase 1 competes with iNOS for the 
same substrate – L-arginine – and produce ornithine as end product. This molecule can be used as 
substrate for others enzymes giving raise to polyamines, which can be used as antioxidants for 
redox regulation (reviewed in (C.C. Portugal 2014). Arginase 1 activity leads to decrease in NO 
production (Chang, Liao et al. 1998) and is associated with an anti-inflammatory signature in 
microglial cells (Rojo, McBean et al. 2014).  
IL-10 is an immunosuppressive cytokine that modulates microglial cell activation by 
inhibiting the production of pro-inflammatory mediators, such as IL-1β, TNF and iNOS (Hanisch 
2002, Park, Lee et al. 2007). The Pfn1 knockdown did not induce significant differences in IL-10 
mRNA expression when compared to control (fig.15B). Altogether, these results indicated that 
Pfn1 reduction lead to a decrease in anti-inflammatory mediators, suggesting that Pfn1 could be 
important for the acquisition of an anti-inflammatory signature by microglial cells. 
Regarding pro-inflammatory mediators, we analysed the activation of transcription factor 
NF-κB and its target genes, glutamate release and ROS production. NF-κB is a multifunctional 
transcription factor that is important for transcription of several pro-inflammatory mediators, 
such as pro-inflammatory cytokines (TNF, IL-6 and IL-1β) and iNOS (Oeckinghaus and Ghosh 2009). 
Firstly, we observed decreased levels of NF-κB in the nucleus of Pfn1 knocked down microglia (fig. 
16A). Consistently, we detected decreased mRNA of pro-inflammatory cytokines (IL-6 and IL-1β) 
and iNOS (fig. 16B-D). Although the differences in pro-inflammatory cytokines should be 
confirmed by enzyme-linked immunosorbent assay (ELISA), these results indicated that Pfn1 
reduction also impacted on the production of pro-inflammatory cytokines and iNOS in microglial 
cells. In fact, there are numerous studies in the vascular disease that support this idea. There are 
studies linking Pfn1 to vascular inflammation, by increasing iNOS activity and peroxynitrite 
production (Romeo, Moulton et al. 2007, Jin, Song et al. 2012) and also by activating signalling 
pathways involved in inflammation, such as p38 mitogen-activated protein kinases (p38 MAPK). 
Romeo and colleagues (2007) showed that both p38 MAPK and iNOS, usually activated upon 
inflammation, were reduced in macrophages from Pfn1 heterozygous mice exposed to oxidized 
low-density lipoproteins. Moreover, spontaneous hypertensive rats with overexpression of Pfn1 
show increase p38 phosphorylation, which was reversed by Pfn1 knockdown, reinforcing that 
Pfn1 impacts the p38 pathway (Wang, Zhang et al. 2014). Although this relationship has to be 
further evaluated, other studies demonstrated that actin remodelling can alter the localization of 
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inflammatory members of the MAPK signalling, including p38 (Yang, Patel et al. 2007). 
Considering that (i) Pfn1 may be involved in p38 MAPK signalling, (ii) p38 MAPK signalling can 
activate NF-κB in microglial cells (Wilms, Rosenstiel et al. 2003) and (iii) NF-κB modulates the 
expression of pro-inflammatory cytokines and iNOS, it is conceivable that Pfn1 would impact on 
pro-inflammatory mediators via p38 signalling. 
As mention above, activated microglia can increase glutamate release (Piani, Spranger et 
al. 1992, Barger and Basile 2001). In microglia, glutamate release can be mediated by the 
increased expression and/or activity of the cystine/glutamate antiporter xc- (Kumar, Singh et al. 
2010) or can be result of TNF induction (Takeuchi, Jin et al. 2006). TNF is able to increase 
glutamate production by up-regulating glutaminase, which generates glutamate from glutamine 
and leads to glutamate release via Cx32 hemichannel. Here, we did not detect significant 
differences in glutamate release between Pfn1 knocked down and control microglia (fig.17). This 
result was consistent with our previous observations that Pfn1 knockdown in microglial cells (i) 
induces no differences in TNF mRNA relative expression comparing to control and (ii) have 
decreased ROS levels, having no increased demands for glutathione biosynthesis and, 
consequently, the activity of xc- transporter might be unaltered. 
Increased ROS production is a hallmark of microglia activation (reviewed in (Rojo, McBean 
et al. 2014). Autocrine effect of ROS can be crucial for microglial pro-inflammatory signature. 
Acting as a second messenger, ROS are capable of modifying gene expression by activating kinase 
cascades and transcription factors, for instance NF-κB and NRF2, while extracellular ROS attack 
pathogens or damaged cells (reviewed in (Block, Zecca et al. 2007). We observed that Pfn1 
knockdown dramatically decreased ROS production in microglia (fig.18) and, Pfn1 knockdown was 
also capable of preventing hypoxia-mediated ROS increase (fig.19). 
 Altogether, (i) the reduction of NF-κB levels in nucleus of Pfn1 knocked down cells, (ii) the 
decreased levels of pro-inflammatory cytokines and iNOS and (iii) the dramatic decrease in ROS 
production, indicated that Pfn1 is crucial for the expression of pro-inflammatory markers, 
suggesting that Pfn1 could be important for the acquisition of a microglial pro-inflammatory 
signature. Since Pfn1 was also important for the expression of anti-inflammatory markers, we 
conclude that Pfn1 is essential for microglial activation, regardless a pro or an anti-inflammatory 
polarization. 
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Given that ROS regulation appears highly dependent on Pfn1 in microglia cells, we aimed 
at investigating the molecular mechanisms by which Pfn1 would affect ROS generation. Firstly, we 
evaluated the effect of Pfn1 knockdown in Rac1 activation, since Rac1 is important for NOX 
assembly and activation (Block and Hong 2005). Our results showed that Pfn1 knockdown 
decreased Rac1 activity (fig. 20B), suggesting that Pfn1 impacts on ROS generation via NOX. 
Previously, Syriani and colleagues (2008), questioned whether Pfn1 overexpression might regulate 
Rac1 activity (Syriani, Gomez-Cabrero et al. 2008). They could not find an increase in Rac1 activity, 
probably because they used an affinity-precipitation assay to measure active Rac-GTP, which is 
less sensitive than the FRET approach we used. We also observed Rac1 activity upon hypoxia. Pfn1 
knockdown kept Rac1 activity at low levels even upon hypoxia, however Rac1 activity did not 
increased in control cells (fig.20C), as expected, given the increase in ROS production in those 
conditions. These results do not refute our hypothesis but highlight the contribution of other ROS 
sources during hypoxia, such as xanthine oxidase activity (Widmer, Engels et al. 2007). Given so, 
we intend to repeat this experiment with other pro-inflammatory stimulus, which classically 
increased ROS production by NOX activity, for instance, LPS. 
In order to understand better the role of Pfn1 in ROS production, we overexpressed 
different Pfn1 mutants in microglia to clarify the importance of different Pfn1 domains in 
modulating ROS production. As described above, Pfn1 actin- and PLP-binding domains are 
independent, however PIP2 binding site overlaps with both (fig.7). For that reason, we used Pfn1 
mutants with point mutations already described in literature, which specifically impaired a single 
binding domain. Pfn1R74E was used as an actin binding domain defective, Pfn1H133S as a PLP binding 
domain defective (Ding, Gau et al. 2009). Also, Pfn1S137D is a phosphomimetic mutation that inhibit 
actin-binding ability (Sathish, Padma et al. 2004, Shao, Welch et al. 2008, Shao and Diamond 
2012). 
We observed decreased ROS content in microglia overexpressing Pfn1 with mutations in 
the actin (Pfn1R74E) and PLP (Pfn1H133S) binding domains in comparison to microglia overexpressing 
Pfn1 WT. However, the phospho-mimetic Pfn1 construct (Pfn1 S137D) was much less effective in 
decreasing ROS production (fig.21). As mention above, phosphorylation on Ser137 leads to 
impairment of actin binding by Pfn1 (Shao, Welch et al. 2008). So, we expected the same result 
for phospho-mimetic Pfn1 and Pfn1 with the mutation in the actin-binding domain. This could be 
just a consequence of the inability of such mutant to fully mimic phosphorylation or could reflect 
a biological difference that should be explored. We think that performing the same experiment 
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with a phospho-resistant Pfn1 mutant could be clarifying. Besides, the effect of Pfn1 interaction 
with phosphatidylinositol in ROS production should also be considered. In fact, it might be 
possible that the inability of Pfn1 to interact with actin and PLP ligands could target Pfn1 to the 
plasma membrane, increasing its binding with PIP2. Pfn1-PIP2 interaction might prevent the 
hydrolysis of PIP2 into DAG and IP3. Reducing DAG and IP3 content might lead to decreased 
activation of protein kinase C and abrogation of protein kinase C-dependent ROS production by 
NOX activation (Welch, Coadwell et al. 2003). 
In light of our results and the existing literature, we believe that Pfn1 affects microglial 
cells, at least in part, via Rac1. We demonstrated that Pfn1 knockdown decreased Rac1 activity, 
both in basal and hypoxic conditions (fig.20), suggesting that Pfn1 might regulate Rac1 activity in 
microglial cells. Rac1 is an important Rho GTPase that regulates NOX and Fcγ receptor-mediated 
phagocytosis (Castellano, Montcourrier et al. 2000), Cheng, Diebold et al. 2006, McCann and 
Roulston 2013). Furthermore, there are evidences indicating that Rac1 activation triggers NRF2 
translocation to nucleus and increases the expression of HO-1 via PI3K/AKT (a KEAP-independent 
regulation of NRF2) (Cuadrado, Martin-Moldes et al. 2014). Moreover, Cuadrado and colleagues 
(2014) demonstrated that Rac1 activates NF-κB through IκBα. In turn, NF-κB modulates NRF2 
activity, which inhibits NF-κB, thus generating a feedback loop (Cuadrado, Martin-Moldes et al. 
2014).  
In conclusion, we hypothesise that Pfn1 reduction leads to a decrease in Rac1 activity, 
which could explain the decrease in phagocytic efficiency and in ROS production. Also, decreased 
Rac1 activity together with decreased ROS production can explain the decrease in pro- and anti-
inflammatory mediators (see fig. 22). The putative regulation of Rac1 by Pfn1 must be explored. 
However, considering that (i) there are several pathways linking PI3K activation to the activation 
of guanine-nucleotide exchange factors (GEFs), which activate Rac1 (Welch, Coadwell et al. 2003, 
Hawkins, Davidson et al. 2007) and (ii) there are several evidences showing that PI3K/AKT 
pathway is sensitive to perturbations in Pfn1 expression (Das, Bae et al. 2009, Jin, Song et al. 
2012), we hypothesised that, in our model, Pfn1 might modulate Rac1 activity via PI3K and 
downstream GEF activation.  
In the future, the role Pfn1 in microglia activation should be addressed using pro- and 
anti-inflammatory stimuli. Also, the putative role of Pfn1 in modulating Rac1 activity and ROS 
production should be addressed. Moreover, in order to confirm and observe the relevance of the 
knockdown of Pfn1 in microglia, we ought to study microglia with targeted deletion of Pfn1 in vivo 
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using Cre-lox conditional knockout mice. Also, considering that Pfn1 knockdown decreases 
microglia activation and ROS production, it would be interesting to study whether Pfn1 
knockdown would be protective in the context of neurodegeneration. 
5. Conclusions  
In this work we investigated the role of Pfn1 in microglial cell function. We observed that 
Pfn1 is more active in hypoxia-challenged microglia and demonstrated that Pfn1 knockdown leads 
to a decrease in microglia-related activation markers. These observations suggest that Pfn1 
modulates pro- and anti-inflammatory signatures in microglial cells. Moreover, we also showed 
that Pfn1 plays a critical role in ROS generation by microglia and it might be involved in Rac1 
regulation.  
  
Figure 22 - Pfn1 might regulate Rac1 mediated inflammation. Rac1 activations induce NF-κB and NRF2 activation; is 
implicated in PI3K and MAPK signalling pathway and regulates NAPDH oxidase activation. Rac1 activation results in 
increase oxidative stress, regulation of inflammation and rearrangements of cytoskeleton involved in phagocytosis. Pfn1 
reduction leads to decreased Rac1 activity which might explain decrease in oxidative stress, inflammation and 
phagocytosis. Adapted from Cuadrado, Martin-Moldes et al. 2014. Rac1-GDP: inactive Rac1; Rac1-GTP:active Rac1; 
MAPK: Mitogen-activated protein kinase; PI3K: phosphatidylinositide 3-kinases; IκB: Inhibitor of NF-κB; ROS: reactive 
oxygen species; NRF2: Nuclear factor erythroid 2–related factor 2; NF-κB: Factor nuclear kappa B. 
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Appendix I - qRT-PCR cycles 
Pro-inflammatory cytokines; profilin 1 and Ywhaz IL-10 NRF2 target genes 
Cycle  Repeats  Steps Duration 
(min) 
Temperature 
(ºC) 
Cycle  Repeats  Steps Duration 
(min) 
Temperature 
(ºC) 
Cycle  Repeats  Steps Duration 
(min) 
Temperature 
(ºC) 
1     1     1      
  1 1 03:00 94   1 1 03:30 95   1 1 03:30 95 
2 
40       
2 
40       
2 
40       
 1 00:15 94ºC  1 00:15 94ºC  1 00:30 94ºC 
 2 00:20 58ºC  2 00:20 62ºC  2 00:30 59ºC 
 3 00:15 70ºC      3 00:30 72ºC 
                
3 81       3 81       3 81       
    1 00:30 55-95     1 00:10 55-95     1 00:10 55-95 
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